Non‐small cell lung cancer in China
In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early‐stage non‐small cell lung cancer (NSCLC) patients miss the optimal timing for...
Saved in:
| Published in | Cancer communications (London, England) Vol. 42; no. 10; pp. 937 - 970 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
John Wiley & Sons, Inc
01.10.2022
John Wiley and Sons Inc Wiley |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early‐stage non‐small cell lung cancer (NSCLC) patients miss the optimal timing for treatment due to the lack of clinical presentations. Population‐based nationwide screening programs are of significant help in increasing the early detection and survival rates of NSCLC in China. The understanding of molecular carcinogenesis and the identification of oncogenic drivers dramatically facilitate the development of targeted therapy for NSCLC, thus prolonging survival in patients with positive drivers. In the exploration of immune escape mechanisms, programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitor monotherapy and PD‐1/PD‐L1 inhibitor plus chemotherapy have become a standard of care for advanced NSCLC in China. In the Chinese Society of Clinical Oncology's guidelines for NSCLC, maintenance immunotherapy is recommended for locally advanced NSCLC after chemoradiotherapy. Adjuvant immunotherapy and neoadjuvant chemoimmunotherapy will be approved for resectable NSCLC. In this review, we summarized recent advances in NSCLC in China in terms of epidemiology, biology, molecular pathology, pathogenesis, screening, diagnosis, targeted therapy, and immunotherapy. |
|---|---|
| AbstractList | In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early‐stage non‐small cell lung cancer (NSCLC) patients miss the optimal timing for treatment due to the lack of clinical presentations. Population‐based nationwide screening programs are of significant help in increasing the early detection and survival rates of NSCLC in China. The understanding of molecular carcinogenesis and the identification of oncogenic drivers dramatically facilitate the development of targeted therapy for NSCLC, thus prolonging survival in patients with positive drivers. In the exploration of immune escape mechanisms, programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitor monotherapy and PD‐1/PD‐L1 inhibitor plus chemotherapy have become a standard of care for advanced NSCLC in China. In the Chinese Society of Clinical Oncology's guidelines for NSCLC, maintenance immunotherapy is recommended for locally advanced NSCLC after chemoradiotherapy. Adjuvant immunotherapy and neoadjuvant chemoimmunotherapy will be approved for resectable NSCLC. In this review, we summarized recent advances in NSCLC in China in terms of epidemiology, biology, molecular pathology, pathogenesis, screening, diagnosis, targeted therapy, and immunotherapy. In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early-stage non-small cell lung cancer (NSCLC) patients miss the optimal timing for treatment due to the lack of clinical presentations. Population-based nationwide screening programs are of significant help in increasing the early detection and survival rates of NSCLC in China. The understanding of molecular carcinogenesis and the identification of oncogenic drivers dramatically facilitate the development of targeted therapy for NSCLC, thus prolonging survival in patients with positive drivers. In the exploration of immune escape mechanisms, programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor monotherapy and PD-1/PD-L1 inhibitor plus chemotherapy have become a standard of care for advanced NSCLC in China. In the Chinese Society of Clinical Oncology's guidelines for NSCLC, maintenance immunotherapy is recommended for locally advanced NSCLC after chemoradiotherapy. Adjuvant immunotherapy and neoadjuvant chemoimmunotherapy will be approved for resectable NSCLC. In this review, we summarized recent advances in NSCLC in China in terms of epidemiology, biology, molecular pathology, pathogenesis, screening, diagnosis, targeted therapy, and immunotherapy.In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early-stage non-small cell lung cancer (NSCLC) patients miss the optimal timing for treatment due to the lack of clinical presentations. Population-based nationwide screening programs are of significant help in increasing the early detection and survival rates of NSCLC in China. The understanding of molecular carcinogenesis and the identification of oncogenic drivers dramatically facilitate the development of targeted therapy for NSCLC, thus prolonging survival in patients with positive drivers. In the exploration of immune escape mechanisms, programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor monotherapy and PD-1/PD-L1 inhibitor plus chemotherapy have become a standard of care for advanced NSCLC in China. In the Chinese Society of Clinical Oncology's guidelines for NSCLC, maintenance immunotherapy is recommended for locally advanced NSCLC after chemoradiotherapy. Adjuvant immunotherapy and neoadjuvant chemoimmunotherapy will be approved for resectable NSCLC. In this review, we summarized recent advances in NSCLC in China in terms of epidemiology, biology, molecular pathology, pathogenesis, screening, diagnosis, targeted therapy, and immunotherapy. Abstract In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early‐stage non‐small cell lung cancer (NSCLC) patients miss the optimal timing for treatment due to the lack of clinical presentations. Population‐based nationwide screening programs are of significant help in increasing the early detection and survival rates of NSCLC in China. The understanding of molecular carcinogenesis and the identification of oncogenic drivers dramatically facilitate the development of targeted therapy for NSCLC, thus prolonging survival in patients with positive drivers. In the exploration of immune escape mechanisms, programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitor monotherapy and PD‐1/PD‐L1 inhibitor plus chemotherapy have become a standard of care for advanced NSCLC in China. In the Chinese Society of Clinical Oncology's guidelines for NSCLC, maintenance immunotherapy is recommended for locally advanced NSCLC after chemoradiotherapy. Adjuvant immunotherapy and neoadjuvant chemoimmunotherapy will be approved for resectable NSCLC. In this review, we summarized recent advances in NSCLC in China in terms of epidemiology, biology, molecular pathology, pathogenesis, screening, diagnosis, targeted therapy, and immunotherapy. |
| Author | Zhou, Caicun Liu, Yunhuan Chen, Peixin Wen, Yaokai |
| AuthorAffiliation | 3 Department of Respiratory and Critical Care Medicine Huadong Hospital Fudan University Shanghai 200040 P. R. China 2 Department of Medical Oncology Shanghai Pulmonary Hospital School of Medicine Tongji University Shanghai 200433 P. R. China 1 School of Medicine Tongji University Shanghai 200092 P. R. China |
| AuthorAffiliation_xml | – name: 3 Department of Respiratory and Critical Care Medicine Huadong Hospital Fudan University Shanghai 200040 P. R. China – name: 1 School of Medicine Tongji University Shanghai 200092 P. R. China – name: 2 Department of Medical Oncology Shanghai Pulmonary Hospital School of Medicine Tongji University Shanghai 200433 P. R. China |
| Author_xml | – sequence: 1 givenname: Peixin orcidid: 0000-0002-4192-8396 surname: Chen fullname: Chen, Peixin organization: Tongji University – sequence: 2 givenname: Yunhuan surname: Liu fullname: Liu, Yunhuan organization: Fudan University – sequence: 3 givenname: Yaokai surname: Wen fullname: Wen, Yaokai organization: Tongji University – sequence: 4 givenname: Caicun surname: Zhou fullname: Zhou, Caicun email: caicunzhoudr@163.com organization: Tongji University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36075878$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kc1qFTEYhoNUbK3deAFyQAoinPrNl_9NoQz-FErd6DpkMpnTHOYkNTOjdNdL8Bq9EnM6rbSluElC8nwPL3lfkp2YoifkdQVHFQB-cNbhUYWU62dkDznSJeVM7dw775KDYVgDQKWVZpy-ILtUgORKqj1yeJ7in-vfw8b2_cL5svRTXC2cjc7nRYiL-iJE-4o872w_-IPbfZ98__TxW_1lefb182l9crZ0gkm9xBagQQTdNtgKpmTLOHgPskPXSYqtxq6xVCjklVcoGS2plGReoBdet3SfnM7eNtm1ucxhY_OVSTaYm4uUV8bmMbjeGxSiqbiylINlDmTTAHWykYI2nqGG4jqeXZdTs_Gt83HMtn8gffgSw4VZpZ9Gc66E0kXw7laQ04_JD6PZhGH7RTb6NA0GZYWKcQWsoG8foes05Vi-qlDIkFFFsVBv7if6F-WujQLADLichiH7zrgw2jGkbcDQmwrMtnOz7dzcdF5G3j8aubM-CVcz_Cv0_uo_pKlPapxn_gLlUrfQ |
| CitedBy_id | crossref_primary_10_1016_j_jconrel_2025_113644 crossref_primary_10_1016_j_snb_2023_134112 crossref_primary_10_1038_s41598_024_60414_x crossref_primary_10_32604_biocell_2024_055753 crossref_primary_10_3389_fimmu_2024_1512349 crossref_primary_10_1186_s12885_024_12624_9 crossref_primary_10_1002_adhm_202404612 crossref_primary_10_1016_j_heliyon_2024_e29404 crossref_primary_10_2147_DDDT_S480402 crossref_primary_10_1038_s41598_024_73177_2 crossref_primary_10_2174_0115680096345676241001081051 crossref_primary_10_1016_j_molstruc_2023_137266 crossref_primary_10_18632_aging_205384 crossref_primary_10_12677_acm_2024_1451629 crossref_primary_10_1016_j_talanta_2024_127162 crossref_primary_10_12677_acm_2024_143972 crossref_primary_10_1186_s13008_023_00105_7 crossref_primary_10_1186_s12944_024_02401_9 crossref_primary_10_1007_s12094_024_03423_6 crossref_primary_10_1515_tjb_2023_0281 crossref_primary_10_1016_j_hlife_2024_01_003 crossref_primary_10_1038_s41419_023_06053_y crossref_primary_10_1016_j_jpha_2024_101154 crossref_primary_10_1186_s12935_024_03549_1 crossref_primary_10_1016_j_bbagen_2024_130706 crossref_primary_10_1016_j_critrevonc_2024_104284 crossref_primary_10_1038_s42003_024_06801_6 crossref_primary_10_12677_ACM_2023_1361446 crossref_primary_10_1620_tjem_2024_J059 crossref_primary_10_1016_j_radmp_2024_05_008 crossref_primary_10_1080_08941939_2024_2445587 crossref_primary_10_1186_s12885_024_12516_y crossref_primary_10_61186_ijrr_22_2_455 crossref_primary_10_3389_fonc_2023_1119575 crossref_primary_10_1038_s41598_024_76413_x crossref_primary_10_1111_bcp_16070 crossref_primary_10_1007_s00210_024_03328_9 crossref_primary_10_1038_s41598_024_82793_x crossref_primary_10_3892_ol_2024_14426 crossref_primary_10_1080_08941939_2024_2381722 crossref_primary_10_2174_0118715206313028240819103933 crossref_primary_10_3389_fgene_2023_1206141 crossref_primary_10_1016_j_ijbiomac_2024_138211 crossref_primary_10_23736_S2724_5985_23_03490_3 crossref_primary_10_3389_fgene_2024_1455502 crossref_primary_10_25259_Cytojournal_59_2024 crossref_primary_10_3724_zdxbyxb_2023_0305 crossref_primary_10_3389_fimmu_2024_1424393 crossref_primary_10_5937_afmnai41_49136 crossref_primary_10_1016_j_critrevonc_2025_104669 crossref_primary_10_1016_j_lungcan_2024_107817 crossref_primary_10_1016_j_lungcan_2025_108508 crossref_primary_10_1038_s41598_024_52034_2 crossref_primary_10_1186_s41065_024_00328_w crossref_primary_10_1016_j_biopha_2023_116097 crossref_primary_10_1111_crj_13764 crossref_primary_10_1007_s10528_023_10641_0 crossref_primary_10_1186_s13062_024_00512_y crossref_primary_10_1186_s12944_023_01960_7 crossref_primary_10_1097_CEJ_0000000000000880 crossref_primary_10_1002_cam4_7227 crossref_primary_10_1016_j_yexcr_2024_113937 crossref_primary_10_1016_j_crad_2024_04_019 crossref_primary_10_1111_cbdd_14435 crossref_primary_10_1515_biol_2025_1065 crossref_primary_10_1002_cbf_4072 crossref_primary_10_1186_s13062_024_00584_w crossref_primary_10_1007_s12672_024_01361_x crossref_primary_10_3389_fonc_2023_1135140 crossref_primary_10_1089_cbr_2024_0141 crossref_primary_10_1615_CritRevEukaryotGeneExpr_2024055827 crossref_primary_10_1016_j_cellsig_2024_111414 crossref_primary_10_1007_s12274_023_6273_y crossref_primary_10_3389_fphar_2025_1533464 crossref_primary_10_62347_MQQB5184 crossref_primary_10_1016_j_yexcr_2024_113962 crossref_primary_10_2147_IJGM_S401225 crossref_primary_10_1016_j_phymed_2024_155690 crossref_primary_10_2147_OTT_S468932 crossref_primary_10_1016_j_clon_2023_07_012 crossref_primary_10_31083_j_fbl2803056 crossref_primary_10_1002_cbin_12197 crossref_primary_10_1186_s12935_025_03690_5 crossref_primary_10_3389_fimmu_2023_1178193 crossref_primary_10_1016_j_arabjc_2024_105603 crossref_primary_10_12677_ACM_2023_13112536 crossref_primary_10_1016_j_radonc_2025_110781 crossref_primary_10_1186_s12957_025_03692_7 crossref_primary_10_12677_ACM_2024_141208 crossref_primary_10_1007_s00210_024_03481_1 crossref_primary_10_3892_ol_2024_14508 crossref_primary_10_1111_cbdd_14450 crossref_primary_10_3390_ijms241713237 crossref_primary_10_1016_j_ijbiomac_2024_132797 crossref_primary_10_3389_fonc_2023_1239451 crossref_primary_10_3390_curroncol30060442 crossref_primary_10_62347_TOYK7025 crossref_primary_10_1007_s12325_023_02679_8 crossref_primary_10_1590_1980_220x_reeusp_2024_0170en crossref_primary_10_3389_fphar_2024_1346383 crossref_primary_10_1159_000540670 crossref_primary_10_3892_ol_2024_14746 crossref_primary_10_1002_slct_202403174 crossref_primary_10_1016_j_medj_2025_100574 crossref_primary_10_1016_j_jvir_2024_10_008 crossref_primary_10_3892_ol_2024_14538 crossref_primary_10_2147_IJN_S473137 crossref_primary_10_31083_j_fbl2808163 crossref_primary_10_1186_s12890_024_02905_1 crossref_primary_10_1177_11795549231215968 crossref_primary_10_2217_fon_2023_0470 crossref_primary_10_1186_s12935_024_03347_9 crossref_primary_10_1039_D3RA03099G crossref_primary_10_1016_j_gene_2024_149002 crossref_primary_10_1016_j_heliyon_2024_e27282 crossref_primary_10_18632_aging_206096 crossref_primary_10_18632_aging_204594 crossref_primary_10_1186_s12906_025_04813_1 crossref_primary_10_1002_ame2_12355 crossref_primary_10_3389_fimmu_2024_1413204 crossref_primary_10_1016_j_intimp_2023_111147 crossref_primary_10_1515_oncologie_2024_0059 crossref_primary_10_1002_tox_24282 crossref_primary_10_1166_jbn_2024_3731 crossref_primary_10_1186_s12885_024_12991_3 crossref_primary_10_12677_acm_2024_1471982 crossref_primary_10_1097_MD_0000000000037218 crossref_primary_10_1016_j_currproblcancer_2023_101036 crossref_primary_10_3389_fonc_2023_1216131 crossref_primary_10_1007_s00262_024_03881_5 crossref_primary_10_32604_or_2024_047490 crossref_primary_10_1002_prm2_12146 crossref_primary_10_1186_s12885_024_12136_6 crossref_primary_10_1136_jitc_2023_008190 crossref_primary_10_1186_s12935_024_03457_4 crossref_primary_10_1016_S1470_2045_24_00599_0 crossref_primary_10_1186_s12889_024_17669_w crossref_primary_10_1007_s11030_023_10789_2 crossref_primary_10_61958_NCYO3401 crossref_primary_10_1007_s00432_023_05586_1 crossref_primary_10_1016_j_arabjc_2024_105891 crossref_primary_10_1002_ctm2_70156 crossref_primary_10_1016_j_biopha_2023_115514 crossref_primary_10_1007_s11033_024_09941_4 crossref_primary_10_1177_11795549231211505 crossref_primary_10_2174_1570180820666230303112514 crossref_primary_10_3390_cancers16030590 crossref_primary_10_1002_jso_27610 crossref_primary_10_3389_fphar_2023_1132158 crossref_primary_10_1177_11795549241257234 crossref_primary_10_1515_biol_2022_0667 crossref_primary_10_3892_ol_2024_14827 crossref_primary_10_1016_j_yexcr_2024_113996 crossref_primary_10_1016_j_radonc_2023_109804 crossref_primary_10_1007_s11010_023_04851_8 crossref_primary_10_1097_JS9_0000000000001479 crossref_primary_10_1038_s41416_024_02678_8 crossref_primary_10_3389_fphar_2023_1227528 crossref_primary_10_1002_EXP_20220170 crossref_primary_10_1016_j_intimp_2024_113564 crossref_primary_10_1186_s12575_024_00259_w crossref_primary_10_1177_15347354241263041 crossref_primary_10_1007_s12094_024_03442_3 crossref_primary_10_3390_diagnostics14212356 crossref_primary_10_1016_j_heliyon_2024_e33888 crossref_primary_10_1016_j_esmoop_2024_103996 crossref_primary_10_1097_MD_0000000000033760 crossref_primary_10_2147_JIR_S493632 crossref_primary_10_32604_or_2024_048562 crossref_primary_10_1002_cncr_35111 crossref_primary_10_1186_s12957_023_03247_8 crossref_primary_10_62347_XQHL4852 crossref_primary_10_3389_fpsyg_2023_1138070 crossref_primary_10_1080_13102818_2024_2338432 crossref_primary_10_5498_wjp_v14_i6_930 crossref_primary_10_3389_fphar_2023_1171302 crossref_primary_10_1016_j_biopha_2023_115171 crossref_primary_10_1111_tra_12951 crossref_primary_10_1016_j_heliyon_2024_e24811 crossref_primary_10_12677_ACM_2023_13102305 crossref_primary_10_1186_s13019_024_03180_1 crossref_primary_10_12677_ACM_2023_1381907 crossref_primary_10_1016_j_ctro_2024_100889 crossref_primary_10_12677_HJBM_2023_134045 crossref_primary_10_1002_ptr_8242 crossref_primary_10_1007_s40336_024_00676_7 crossref_primary_10_1080_14786419_2024_2432610 crossref_primary_10_1021_acs_jproteome_4c00344 crossref_primary_10_1016_j_chroma_2023_464448 crossref_primary_10_1016_j_isci_2024_110832 crossref_primary_10_1097_CAD_0000000000001577 crossref_primary_10_1016_j_jtho_2024_01_013 crossref_primary_10_1038_s41598_024_73080_w crossref_primary_10_1016_j_lfs_2023_122033 crossref_primary_10_1016_j_talanta_2023_125444 crossref_primary_10_1016_j_ijbiomac_2024_132058 crossref_primary_10_3389_fonc_2024_1433505 crossref_primary_10_3389_fonc_2024_1467722 crossref_primary_10_3389_fimmu_2023_1161718 crossref_primary_10_3389_fonc_2024_1376502 crossref_primary_10_1111_iwj_14701 crossref_primary_10_1002_mp_17414 crossref_primary_10_1186_s40658_024_00685_5 crossref_primary_10_3390_molecules28134947 crossref_primary_10_3724_zdxbyxb_2023_0256 crossref_primary_10_3892_ol_2025_14954 crossref_primary_10_1007_s00432_023_05490_8 crossref_primary_10_3389_fpubh_2023_1137255 crossref_primary_10_3390_ijms24076520 crossref_primary_10_1016_j_intimp_2024_111918 crossref_primary_10_1016_j_jep_2023_116948 crossref_primary_10_1016_j_bbrc_2023_149344 crossref_primary_10_3389_fonc_2023_1180723 crossref_primary_10_1186_s13578_025_01358_1 crossref_primary_10_3389_fimmu_2025_1555216 crossref_primary_10_62347_EAAF2821 crossref_primary_10_1002_cac2_12627 crossref_primary_10_1080_17520363_2024_2404379 crossref_primary_10_2174_0113816128330530240918073721 crossref_primary_10_1186_s40644_025_00826_8 crossref_primary_10_1016_j_carbpol_2024_122521 crossref_primary_10_1007_s12033_024_01198_3 crossref_primary_10_1111_crj_70041 crossref_primary_10_1021_acsomega_4c07295 crossref_primary_10_1136_spcare_2023_004325 crossref_primary_10_2147_CLEP_S442152 crossref_primary_10_1186_s12935_024_03250_3 crossref_primary_10_1016_j_intimp_2024_113809 crossref_primary_10_1007_s10528_023_10526_2 crossref_primary_10_2174_0115680096284068240506095417 crossref_primary_10_1016_j_ejphar_2024_177131 crossref_primary_10_3892_ol_2023_14158 crossref_primary_10_2174_0118715206296807240717165200 crossref_primary_10_3390_cancers16132338 crossref_primary_10_1016_j_neo_2024_101077 crossref_primary_10_1016_j_jpsychores_2023_111374 crossref_primary_10_1186_s10020_024_01018_z crossref_primary_10_1002_cac2_12633 crossref_primary_10_3389_fimmu_2023_1276107 crossref_primary_10_1186_s12951_024_02883_w crossref_primary_10_2147_IJGM_S409006 crossref_primary_10_1038_s41698_024_00658_y crossref_primary_10_1016_j_jddst_2023_104346 crossref_primary_10_1007_s12672_024_01552_6 crossref_primary_10_1186_s12885_025_13859_w crossref_primary_10_1007_s12094_023_03376_2 crossref_primary_10_1186_s12885_023_11221_6 crossref_primary_10_1177_15330338241282080 crossref_primary_10_1111_crj_13712 crossref_primary_10_1016_j_ijbiomac_2024_133594 crossref_primary_10_1038_s41598_024_83947_7 crossref_primary_10_1186_s12885_024_12390_8 crossref_primary_10_1038_s41598_024_74490_6 crossref_primary_10_1016_j_crphar_2024_100212 crossref_primary_10_1021_acs_jafc_2c06723 crossref_primary_10_1007_s00726_023_03361_7 crossref_primary_10_1016_j_radonc_2024_110325 crossref_primary_10_2147_DDDT_S449139 crossref_primary_10_1007_s00262_024_03666_w crossref_primary_10_1016_j_prp_2023_154959 crossref_primary_10_1007_s40265_023_01946_w crossref_primary_10_1016_j_prp_2023_154719 crossref_primary_10_25259_Cytojournal_71_2024 crossref_primary_10_2147_CMAR_S472196 crossref_primary_10_1186_s13020_024_00895_0 crossref_primary_10_1016_j_ecoenv_2024_117157 crossref_primary_10_1080_17425255_2023_2260738 crossref_primary_10_1016_j_intimp_2024_113588 crossref_primary_10_1177_10732748241307363 crossref_primary_10_3389_fpubh_2024_1425734 crossref_primary_10_1096_fj_202402139R crossref_primary_10_1002_cam4_6616 crossref_primary_10_1016_j_clnesp_2023_12_018 crossref_primary_10_1016_j_jpha_2024_03_002 crossref_primary_10_1016_j_phymed_2023_155087 crossref_primary_10_1155_2024_8660434 crossref_primary_10_3390_plants13020290 crossref_primary_10_1080_15384047_2024_2328382 crossref_primary_10_1038_s41467_024_45769_z crossref_primary_10_1111_jcmm_70218 crossref_primary_10_1111_cbdd_14507 crossref_primary_10_1016_j_phymed_2023_155093 crossref_primary_10_12677_acm_2024_1482354 crossref_primary_10_1016_j_jff_2025_106729 crossref_primary_10_3390_toxics13030210 crossref_primary_10_1186_s12957_024_03434_1 crossref_primary_10_1002_jcp_31370 crossref_primary_10_1080_07391102_2023_2262587 crossref_primary_10_1186_s12943_024_02215_4 crossref_primary_10_1016_j_heliyon_2024_e29290 crossref_primary_10_1186_s12964_023_01281_3 crossref_primary_10_62347_STSI5751 |
| Cites_doi | 10.1111/1759-7714.12121 10.1200/JCO.2019.37.15_suppl.8503 10.21037/tlcr-20-455 10.1056/NEJMoa2004407 10.1016/0277-9536(94)90314-X 10.1016/j.jtho.2021.09.014 10.1056/NEJMoa1406766 10.2147/CMAR.S282617 10.1371/journal.pmed.1002118 10.1056/NEJMoa2005653 10.1016/S2213-2600(18)30277-7 10.1056/NEJMoa1408440 10.1056/NEJMoa1102873 10.1016/j.jtho.2021.08.112 10.1200/JCO.2009.27.6204 10.1093/annonc/mds578 10.1016/j.jtho.2021.11.018 10.1007/s00432-015-2081-4 10.1016/j.envint.2015.11.007 10.21037/tlcr-20-1132 10.1056/NEJMoa1713137 10.3390/s20102837 10.1186/s13000-017-0683-7 10.1016/j.jtho.2018.06.012 10.3322/caac.21632 10.1016/j.cmpb.2022.106660 10.7150/jca.51445 10.1001/jama.2014.3741 10.1016/j.jtho.2016.11.2225 10.1159/000487243 10.20892/j.issn.2095-3941.2020.0212 10.1016/j.annonc.2021.08.2120 10.1200/JCO.21.00662 10.1016/S2213-2600(19)30053-0 10.1164/rccm.201901-0096OC 10.1007/s40265-017-0776-3 10.1097/JTO.0000000000000043 10.1056/NEJMoa043623 10.1016/j.jtho.2020.09.001 10.1001/jamaoncol.2018.3039 10.1016/S1470-2045(06)70804-X 10.1016/j.jtho.2021.04.011 10.1093/annonc/mdy121 10.1056/NEJMoa061884 10.2188/jea.JE20110049 10.1200/JCO.2021.39.15_suppl.8503 10.1007/s00280-018-3597-5 10.1016/j.lungcan.2013.06.025 10.1016/S2213-2600(21)00084-9 10.1016/j.lungcan.2018.01.003 10.1097/JTO.0b013e31824c7f7a 10.1016/j.jtho.2021.10.024 10.1056/NEJMoa1917346 10.1093/jnci/86.9.673 10.1056/NEJMoa2103695 10.1016/j.jtho.2020.10.155 10.21037/jtd.2017.08.61 10.1200/JCO.2011.39.5848 10.1038/nrclinonc.2014.104 10.1200/JCO.2002.02.068 10.1093/jnci/djq346 10.21037/tcr.2019.07.10 10.1016/j.jtho.2020.04.028 10.1097/PPO.0000000000000101 10.1155/2017/8314740 10.1016/j.lungcan.2019.06.012 10.5858/133.10.1552 10.1001/jamaoncol.2021.3523 10.1158/0008-5472.CAN-04-0083 10.1038/nature12796 10.1002/ijc.32033 10.1097/JTO.0000000000000630 10.1001/jamaoncol.2016.5945 10.1056/NEJM197111182852108 10.1001/jamainternmed.2013.12738 10.1056/NEJMoa2027187 10.1056/NEJMoa2027071 10.1200/JCO.2009.23.2272 10.1200/JCO.2014.59.4424 10.1097/JTO.0000000000000033 10.1371/journal.pone.0183331 10.1007/s00268-017-4086-4 10.1056/NEJMoa1709937 10.1136/thoraxjnl-2015-208054 10.1016/S2213-2600(21)00134-X 10.1016/j.jncc.2020.12.001 10.1016/j.jtho.2021.01.320 10.1200/JCO.2015.64.8824 10.21037/tlcr-2020-63 10.1016/S1470-2045(21)00650-1 10.1158/1055-9965.EPI-10-0437 10.1016/S0140-6736(18)32409-7 10.1016/j.pupt.2021.102084 10.4103/0970-9371.126640 10.1200/JCO.2016.70.3223 10.1200/JCO.2009.22.6993 10.1016/j.envres.2019.108748 10.6004/jnccn.2012.0062 10.1016/S1470-2045(21)00630-6 10.1002/cac2.12227 10.1001/jama.2019.3241 10.1056/NEJMoa1913662 10.1016/S1470-2045(17)30679-4 10.1200/JCO.2016.71.3701 10.1111/1759-7714.13577 10.1093/annonc/mdv381 10.1200/JCO.2018.77.9777 10.1186/s40364-020-00199-z 10.1038/s41416-019-0573-8 10.1093/annonc/mdy405 10.1016/j.jtcvs.2009.08.026 10.1001/jama.2013.284692 10.21037/jtd.2018.03.81 10.1200/JCO.2021.39.15_suppl.9008 10.1093/annonc/mdx009 10.1038/513S2a 10.1097/JTO.0b013e31819cce50 10.1001/jamaoncol.2016.6416 10.1056/NEJMoa031644 10.1016/S1470-2045(15)70046-X 10.1200/JCO.2007.13.9030 10.1016/j.jtho.2020.07.014 10.1097/RTI.0000000000000538 10.1056/NEJMoa1716948 10.3892/or.2016.4874 10.1016/j.jtho.2021.08.111 10.1002/cncy.21286 10.1016/S0140-6736(21)02098-5 10.1016/j.jtho.2018.08.154 10.21037/atm.2020.01.135 10.1593/tlo.13535 10.1073/pnas.0702916104 10.1186/s12885-018-4277-x 10.1016/j.jtho.2019.01.020 10.1200/JCO.2016.66.9218 10.1038/nature05945 10.1002/cac2.12099 10.1016/j.annonc.2022.02.095 10.1038/s41591-018-0007-9 10.3389/fonc.2021.774156 10.2147/COPD.S158818 10.1002/cac2.12153 10.1016/j.lungcan.2015.11.006 10.1245/s10434-009-0808-7 10.1016/j.ejca.2017.07.036 10.1002/mp.12820 10.1016/j.lungcan.2019.05.008 10.1200/JCO.19.01488 10.1038/ng.875 10.1016/j.lungcan.2018.05.002 10.1371/journal.pone.0080458 10.1200/JCO.2020.38.15_suppl.9515 10.1016/j.cllc.2017.10.004 10.1158/1055-9965.EPI-16-0794 10.1016/j.jtho.2021.10.014 10.1016/S2213-2600(19)30252-8 10.1200/JCO.2009.24.0333 10.1200/JCO.2006.08.2826 10.1016/S2213-2600(20)30455-0 10.1016/j.lungcan.2017.08.021 10.3389/fonc.2021.609054 10.1200/JCO.2003.12.046 10.1016/S0140-6736(16)31473-8 10.3322/caac.21708 10.1016/j.jtho.2021.08.181 10.1016/S0140-6736(12)61085-X 10.1016/j.jtho.2018.12.013 10.1007/s11548-019-02097-8 10.1016/j.chest.2017.12.027 10.1002/cncr.27940 10.1158/1055-9965.EPI-18-0356 10.1126/scitranslmed.3007094 10.1016/j.prp.2020.152873 10.1200/JCO.2008.16.4855 10.1002/ijc.30447 10.1159/000338519 10.1056/NEJMoa1612674 10.1200/JCO.2009.26.1685 10.1016/S0140-6736(13)62159-5 10.1016/S0140-6736(17)30123-X 10.1016/j.jtho.2021.03.025 10.1200/JCO.20.01820 10.1016/S1470-2045(20)30453-8 10.1200/JCO.19.01154 10.1007/s00204-016-1771-2 10.1016/j.jtho.2015.09.014 10.1200/JCO.2007.15.0375 10.1016/S2213-2600(20)30365-9 10.1056/NEJMoa1809697 10.1056/NEJMoa011954 10.1016/j.lungcan.2021.12.002 10.1093/ejcts/ezt015 10.1007/s11523-021-00794-6 10.1200/JCO.2009.26.2543 10.1002/cac2.12225 10.1016/j.sleep.2021.06.044 10.1001/jamaoncol.2021.2301 10.3322/caac.21660 10.1038/s41591-019-0716-8 10.1097/CM9.0000000000001474 10.1038/nrclinonc.2013.136 10.3390/ijerph19031164 10.1371/journal.pone.0046144 10.1200/JCO.21.00174 10.1016/j.jtho.2021.04.013 10.1200/JCO.2017.75.5587 10.1007/s00432-016-2211-7 10.1164/rccm.200807-1068OC 10.1056/NEJMoa2002787 10.1093/annonc/mdi126 10.1186/s12885-017-3451-x 10.1016/S1470-2045(10)70087-5 10.1016/j.lungcan.2019.01.016 10.1002/ijc.30806 10.1200/JCO.2012.45.2011 10.1200/JCO.21.02752 10.1016/j.annonc.2020.10.479 10.1016/j.jtho.2021.02.016 10.1200/JCO.2007.14.5466 10.1016/j.jtho.2020.11.026 10.1093/jnci/djab143 10.1016/j.jtho.2016.11.2228 10.1001/jamainternmed.2018.3056 10.1016/j.mri.2012.06.010 10.1186/1476-4598-9-188 10.1097/MCP.0000000000000349 10.1093/aje/kwz187 10.18632/oncotarget.5549 10.7150/jca.35127 10.1136/jech-2013-203675 10.1038/s41598-021-84012-3 10.1378/chest.07-1349 10.1093/jnci/djr325 10.1016/S2542-5196(20)30161-3 10.1007/s12011-020-02240-6 10.1200/JCO.2014.60.0130 10.1016/j.critrevonc.2016.02.012 10.1016/j.jtho.2021.05.005 10.1016/S2213-2600(19)30144-4 10.1001/jamaoncol.2021.0366 10.1016/j.jtho.2018.12.006 10.1111/ajco.13664 10.1097/JTO.0000000000000130 10.1136/jitc-2021-003027 10.1038/s41379-019-0339-0 10.21037/tlcr-20-608 10.1056/NEJMoa1916623 10.1016/j.cllc.2020.06.016 10.1016/j.jtocrr.2021.100163 10.1056/NEJM199401203300301 10.1007/s40265-018-0916-4 10.1007/s11604-013-0264-y 10.1200/JCO.2005.01.0793 10.7150/jca.16856 10.3322/caac.21675 10.1016/j.jtho.2019.03.007 10.1016/j.jtho.2021.06.017 10.1001/jamaoncol.2021.4761 10.1097/JTO.0000000000000606 10.1200/JCO.18.00131 10.1016/j.cell.2007.11.025 10.1007/s10278-020-00355-9 10.1007/s11523-016-0460-7 10.1016/S1470-2045(17)30680-0 10.1200/JCO.2001.19.13.3210 10.1016/j.jtho.2020.01.017 10.1016/S2213-2600(19)30084-0 10.1097/JTO.0000000000000146 10.1002/ijc.29020 10.1038/ng.2351 10.1002/cam4.2183 10.1200/JCO.20.00505 10.1016/j.jtho.2021.07.009 10.1111/1759-7714.12859 10.3390/ijerph181910418 10.1016/j.jtho.2018.05.013 10.1038/ng.3892 10.1056/NEJMoa2112431 10.1093/jnci/dju284 10.1093/annonc/mdl377 10.1200/JCO.18.00149 10.1200/JCO.20.00297 10.1200/JCO.2003.03.195 10.1200/JCO.2021.39.15_suppl.9066 10.1158/1078-0432.CCR-08-0168 10.1016/j.athoracsur.2019.08.017 |
| ContentType | Journal Article |
| Copyright | 2022 The Authors. published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center. 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center. 2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2022 The Authors. published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center. – notice: 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center. – notice: 2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9- K9. KB0 M0R M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1002/cac2.12359 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central (subscription) ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Consumer Health Database Health & Medical Collection (Alumni) Medical Database (ProQuest) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | CHEN et al |
| EISSN | 2523-3548 |
| EndPage | 970 |
| ExternalDocumentID | oai_doaj_org_article_266b158a350a4c07bb03c7b763be4290 PMC9558689 36075878 10_1002_cac2_12359 CAC212359 |
| Genre | reviewArticle Journal Article Review |
| GeographicLocations | United States--US China |
| GeographicLocations_xml | – name: China – name: United States--US |
| GrantInformation_xml | – fundername: Science and Technology Innovation Action Plan Project of Shanghai Municipal Science and Technology Commission funderid: 19411950300; 19411950301 – fundername: National Natural Science Foundation of China funderid: 81871865 – fundername: Collaborative Innovation Program of Shanghai Municipal Health Commission funderid: 2020CXJQ02 – fundername: Collaborative Innovation Program of Shanghai Municipal Health Commission grantid: 2020CXJQ02 – fundername: ; grantid: 81871865 – fundername: Science and Technology Innovation Action Plan Project of Shanghai Municipal Science and Technology Commission grantid: 19411950300; 19411950301 |
| GroupedDBID | 0R~ 1OC 24P 7RV 7X7 88E 8FI 8FJ ABUWG ACCMX ACRMQ ACXQS ADKYN ADPDF ADUKV ADZMN ADZOD AFKRA AHSBF ALMA_UNASSIGNED_HOLDINGS ALUQN AMKLP AVUZU AZQEC BENPR BMC C24 C6C CCPQU EBS EJD FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW ITC K9- M0R M1P M~E NAPCQ OK1 OVD OVEED PIMPY PSQYO ROL RPM RSV SOJ TEORI UKHRP WIN AAYXX CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM PJZUB PPXIY 3V. 7XB 8FK DWQXO K9. PKEHL PQEST PQQKQ PQUKI 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c6479-2d00b2209db2d6487d450ee07f2cf732d92fba368251e82743000874e62e6e9d3 |
| IEDL.DBID | 7X7 |
| ISSN | 2523-3548 |
| IngestDate | Wed Aug 27 01:24:03 EDT 2025 Thu Aug 21 18:40:08 EDT 2025 Thu Jul 10 22:08:16 EDT 2025 Wed Aug 13 04:31:24 EDT 2025 Mon Jul 21 05:57:37 EDT 2025 Tue Jul 01 02:29:16 EDT 2025 Thu Apr 24 23:04:47 EDT 2025 Wed Jan 22 17:21:46 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | non-small cell lung cancer targeted therapy screening clinical guidelines programmed death-ligand 1 (PD-L1) immunotherapy clinical trials programmed cell death protein 1 (PD-1) epidermal growth factor receptor (EGFR) mutation |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c6479-2d00b2209db2d6487d450ee07f2cf732d92fba368251e82743000874e62e6e9d3 |
| Notes | Peixin Chen, Yunhuan Liu and Yaokai Wen contributed equally ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-4192-8396 |
| OpenAccessLink | https://www.proquest.com/docview/2724243832?pq-origsite=%requestingapplication% |
| PMID | 36075878 |
| PQID | 2724243832 |
| PQPubID | 2040150 |
| PageCount | 34 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_266b158a350a4c07bb03c7b763be4290 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9558689 proquest_miscellaneous_2712845804 proquest_journals_2724243832 pubmed_primary_36075878 crossref_citationtrail_10_1002_cac2_12359 crossref_primary_10_1002_cac2_12359 wiley_primary_10_1002_cac2_12359_CAC212359 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | October 2022 |
| PublicationDateYYYYMMDD | 2022-10-01 |
| PublicationDate_xml | – month: 10 year: 2022 text: October 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Cancer communications (London, England) |
| PublicationTitleAlternate | Cancer Commun (Lond) |
| PublicationYear | 2022 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | 2017; 84 2020; 20 2019; 14 2020; 15 2020; 11 2013; 121 2021; 71 2016; 36 2012; 10 2016; 34 2022; 163 2013; 119 2015; 136 2017; 77 2019; 28 2008; 26 2019; 393 2012; 22 2011; 365 2010; 9 2021; 81 2007; 18 2021; 43 2020; 383 2020; 382 2020; 40 2019; 37 2020; 38 2009; 179 2020; 33 2021; 50 2017; 376 2017; 377 2019; 188 2016; 13 2012; 30 2014; 311 2016; 11 2006; 355 2018; 117 2022; 4 2019; 179 2020; 26 2013; 81 2017; 140 2018; 95 2017; 141 2020; 21 2016; 27 2012; 44 2016; 26 2017; 389 2020; 29 1994; 330 2017; 41 2004; 64 2013; 24 2017; 49 2017; 44 2016; 101 2014; 68 2018; 82 2017; 113 2014; 174 2020; 8 2014; 5 2020; 4 2013; 10 2007; 132 2017; 35 2007; 131 2020; 9 2001; 19 2002; 346 2014; 9 2018; 78 2014; 6 2007; 25 2021; 9 2017; 20 2021; 7 2014; 513 2015; 6 2021; 87 2015; 4 2021; 2 2012 2017; 2017 2013; 44 2017; 28 2017; 23 2008 2021; 1 2020; 109 2011; 103 2022 2002; 20 2017; 17 2010; 139 2020; 70 2013; 30 2017; 12 2017; 18 2009; 4 2007; 104 2010; 19 2010; 17 2010; 102 2014; 27 2016; 388 2022; 23 2014; 26 2014; 371 2020; 201 1971; 285 2018; 45 2013; 8 2022; 216 2013; 6 2016; 142 2019; 321 2018; 6 2018; 9 2018; 4 2021; 398 2010; 28 2022; 40 2018; 178 2020; 216 2022; 37 2022; 33 2014; 11 2018; 36 2019; 8 2019; 7 2018; 29 2007; 448 2005; 352 2013; 503 1983; 71 2021; 384 2016; 91 2018; 21 2018; 27 2022; 114 1994; 86 2018; 24 2018; 19 2018; 18 2021; 134 2014; 36 2022; 10 2005; 16 2018; 10 2014; 383 2022; 17 2003; 21 2014; 32 2022; 19 2018; 13 2018; 121 2017; 8 2017; 3 2021; 22 2022; 72 2015; 33 2011; 12 2016; 71 2012; 56 2017; 9 2005; 23 2019; 121 2021; 36 2021; 32 2016; 90 2021; 39 2018; 379 2018; 378 2016; 87 1994; 38 2021; 199 2021; 41 2015; 16 2012; 380 2015; 10 2008; 14 2006; 7 2009; 133 2022; 42 2009; 27 2019; 145 2018; 153 2022; 386 2021; 13 2021; 16 2014; 106 2021; 10 2021; 12 2021; 11 2021; 18 2004; 350 2021; 17 2015; 22 2015; 21 2011; 43 2011; 45 2012; 7 2019; 130 2019; 133 2019; 134 e_1_2_16_23_1 e_1_2_16_46_1 e_1_2_16_222_1 e_1_2_16_260_1 e_1_2_16_69_1 e_1_2_16_283_1 e_1_2_16_113_1 e_1_2_16_136_1 e_1_2_16_159_1 e_1_2_16_84_1 e_1_2_16_305_1 e_1_2_16_61_1 WANG W (e_1_2_16_107_1) 2012 e_1_2_16_162_1 e_1_2_16_185_1 Wang N (e_1_2_16_14_1) 2011; 45 e_1_2_16_234_1 e_1_2_16_219_1 e_1_2_16_257_1 e_1_2_16_19_1 e_1_2_16_34_1 e_1_2_16_57_1 e_1_2_16_210_1 e_1_2_16_233_1 e_1_2_16_271_1 e_1_2_16_294_1 e_1_2_16_11_1 e_1_2_16_109_1 e_1_2_16_124_1 e_1_2_16_147_1 e_1_2_16_95_1 e_1_2_16_72_1 e_1_2_16_9_1 e_1_2_16_196_1 e_1_2_16_150_1 e_1_2_16_245_1 e_1_2_16_268_1 e_1_2_16_45_1 e_1_2_16_68_1 e_1_2_16_200_1 e_1_2_16_261_1 e_1_2_16_284_1 e_1_2_16_22_1 e_1_2_16_60_1 e_1_2_16_83_1 e_1_2_16_114_1 e_1_2_16_306_1 e_1_2_16_137_1 e_1_2_16_186_1 e_1_2_16_140_1 e_1_2_16_212_1 e_1_2_16_235_1 Liu L (e_1_2_16_65_1) 2017; 20 e_1_2_16_258_1 e_1_2_16_18_1 e_1_2_16_56_1 e_1_2_16_211_1 e_1_2_16_295_1 e_1_2_16_79_1 e_1_2_16_272_1 e_1_2_16_33_1 e_1_2_16_71_1 e_1_2_16_94_1 e_1_2_16_10_1 e_1_2_16_125_1 e_1_2_16_148_1 e_1_2_16_197_1 e_1_2_16_151_1 e_1_2_16_174_1 Shao W (e_1_2_16_157_1) 2014; 26 e_1_2_16_223_1 e_1_2_16_246_1 e_1_2_16_208_1 e_1_2_16_269_1 e_1_2_16_266_1 e_1_2_16_29_1 e_1_2_16_67_1 e_1_2_16_243_1 e_1_2_16_281_1 Zhang LM (e_1_2_16_16_1) 2008 e_1_2_16_220_1 e_1_2_16_119_1 e_1_2_16_44_1 e_1_2_16_303_1 e_1_2_16_21_1 e_1_2_16_82_1 e_1_2_16_122_1 e_1_2_16_145_1 Chun‐Fang Z (e_1_2_16_106_1) 2015; 22 PM F (e_1_2_16_173_1) 2021; 81 e_1_2_16_160_1 e_1_2_16_183_1 e_1_2_16_278_1 e_1_2_16_217_1 Jia Z (e_1_2_16_128_1) 2022; 37 e_1_2_16_254_1 e_1_2_16_277_1 e_1_2_16_292_1 e_1_2_16_78_1 e_1_2_16_231_1 e_1_2_16_32_1 e_1_2_16_55_1 e_1_2_16_70_1 e_1_2_16_168_1 e_1_2_16_93_1 e_1_2_16_110_1 e_1_2_16_156_1 e_1_2_16_133_1 Gao Z (e_1_2_16_104_1) 2017; 44 e_1_2_16_3_1 e_1_2_16_171_1 e_1_2_16_194_1 e_1_2_16_205_1 e_1_2_16_289_1 e_1_2_16_228_1 Xiaoyang L (e_1_2_16_103_1) 2016; 26 e_1_2_16_221_1 e_1_2_16_244_1 e_1_2_16_282_1 e_1_2_16_89_1 e_1_2_16_2_1 e_1_2_16_43_1 e_1_2_16_304_1 e_1_2_16_135_1 e_1_2_16_20_1 e_1_2_16_81_1 e_1_2_16_158_1 e_1_2_16_123_1 e_1_2_16_100_1 e_1_2_16_184_1 e_1_2_16_161_1 Yuan H (e_1_2_16_66_1) 2022; 4 e_1_2_16_218_1 e_1_2_16_256_1 e_1_2_16_279_1 Harris JE (e_1_2_16_8_1) 1983; 71 e_1_2_16_39_1 e_1_2_16_255_1 e_1_2_16_232_1 e_1_2_16_270_1 e_1_2_16_293_1 e_1_2_16_31_1 e_1_2_16_77_1 e_1_2_16_54_1 e_1_2_16_108_1 e_1_2_16_146_1 e_1_2_16_92_1 e_1_2_16_169_1 e_1_2_16_111_1 e_1_2_16_134_1 e_1_2_16_195_1 e_1_2_16_172_1 e_1_2_16_229_1 e_1_2_16_267_1 Begum S (e_1_2_16_163_1) 2014; 6 e_1_2_16_264_1 e_1_2_16_309_1 e_1_2_16_287_1 e_1_2_16_301_1 e_1_2_16_27_1 Kohno T (e_1_2_16_28_1) 2015; 4 e_1_2_16_241_1 e_1_2_16_117_1 e_1_2_16_42_1 e_1_2_16_88_1 e_1_2_16_120_1 e_1_2_16_143_1 e_1_2_16_166_1 e_1_2_16_189_1 e_1_2_16_80_1 Zou XN (e_1_2_16_17_1) 2014; 27 e_1_2_16_181_1 e_1_2_16_215_1 e_1_2_16_238_1 e_1_2_16_15_1 e_1_2_16_38_1 e_1_2_16_252_1 e_1_2_16_275_1 e_1_2_16_298_1 e_1_2_16_30_1 e_1_2_16_53_1 e_1_2_16_76_1 e_1_2_16_290_1 Chen WQ (e_1_2_16_102_1) 2020; 29 e_1_2_16_91_1 e_1_2_16_131_1 e_1_2_16_177_1 e_1_2_16_154_1 e_1_2_16_5_1 e_1_2_16_192_1 e_1_2_16_226_1 e_1_2_16_249_1 e_1_2_16_26_1 e_1_2_16_49_1 e_1_2_16_265_1 e_1_2_16_288_1 e_1_2_16_302_1 e_1_2_16_242_1 e_1_2_16_41_1 e_1_2_16_64_1 e_1_2_16_87_1 e_1_2_16_118_1 e_1_2_16_280_1 e_1_2_16_179_1 e_1_2_16_121_1 e_1_2_16_167_1 e_1_2_16_144_1 e_1_2_16_182_1 Tang W (e_1_2_16_105_1) 2014; 36 e_1_2_16_216_1 e_1_2_16_239_1 e_1_2_16_253_1 e_1_2_16_299_1 e_1_2_16_276_1 e_1_2_16_37_1 e_1_2_16_230_1 e_1_2_16_98_1 DR S (e_1_2_16_203_1) 2021; 39 e_1_2_16_52_1 e_1_2_16_129_1 e_1_2_16_291_1 e_1_2_16_75_1 e_1_2_16_90_1 e_1_2_16_132_1 e_1_2_16_155_1 e_1_2_16_178_1 e_1_2_16_4_1 e_1_2_16_193_1 e_1_2_16_170_1 e_1_2_16_204_1 e_1_2_16_227_1 Chen WQ (e_1_2_16_101_1) 2019; 28 e_1_2_16_25_1 Zhou Q (e_1_2_16_207_1) 2022; 23 e_1_2_16_285_1 e_1_2_16_48_1 e_1_2_16_262_1 e_1_2_16_63_1 e_1_2_16_86_1 e_1_2_16_115_1 e_1_2_16_138_1 e_1_2_16_40_1 e_1_2_16_307_1 e_1_2_16_164_1 e_1_2_16_187_1 e_1_2_16_141_1 e_1_2_16_310_1 e_1_2_16_236_1 e_1_2_16_213_1 e_1_2_16_259_1 e_1_2_16_13_1 e_1_2_16_296_1 e_1_2_16_36_1 e_1_2_16_59_1 e_1_2_16_250_1 e_1_2_16_273_1 e_1_2_16_74_1 e_1_2_16_97_1 e_1_2_16_51_1 Zhou Q (e_1_2_16_112_1) 2018; 21 e_1_2_16_126_1 e_1_2_16_149_1 e_1_2_16_7_1 e_1_2_16_209_1 e_1_2_16_198_1 e_1_2_16_175_1 e_1_2_16_152_1 e_1_2_16_201_1 e_1_2_16_247_1 e_1_2_16_190_1 e_1_2_16_224_1 e_1_2_16_240_1 e_1_2_16_263_1 e_1_2_16_286_1 e_1_2_16_308_1 e_1_2_16_24_1 e_1_2_16_47_1 e_1_2_16_300_1 e_1_2_16_139_1 e_1_2_16_85_1 He J (e_1_2_16_99_1) 2021; 43 e_1_2_16_62_1 e_1_2_16_116_1 e_1_2_16_142_1 e_1_2_16_188_1 e_1_2_16_165_1 Zhou Q (e_1_2_16_206_1) 2020; 9 e_1_2_16_214_1 e_1_2_16_237_1 e_1_2_16_180_1 e_1_2_16_274_1 e_1_2_16_12_1 e_1_2_16_297_1 e_1_2_16_35_1 e_1_2_16_58_1 e_1_2_16_251_1 e_1_2_16_96_1 e_1_2_16_73_1 e_1_2_16_50_1 e_1_2_16_127_1 e_1_2_16_199_1 e_1_2_16_153_1 e_1_2_16_176_1 e_1_2_16_6_1 e_1_2_16_130_1 e_1_2_16_202_1 e_1_2_16_225_1 e_1_2_16_248_1 e_1_2_16_191_1 |
| References_xml | – volume: 4 start-page: 156 issue: 2 year: 2015 end-page: 64 article-title: Beyond ALK‐RET, ROS1 and other oncogene fusions in lung cancer publication-title: Transl Lung Cancer Res – volume: 56 start-page: 419 issue: 4 year: 2012 end-page: 24 article-title: Subclassification of non‐small cell lung cancer by cytologic sampling: a logical approach with selective use of immunocytochemistry publication-title: Acta Cytol – volume: 87 start-page: 66 year: 2016 end-page: 73 article-title: Particulate matter air pollution components and risk for lung cancer publication-title: Environ Int – volume: 18 start-page: 1590 issue: 12 year: 2017 end-page: 9 article-title: Lorlatinib in non‐small‐cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open‐label, single‐arm first‐in‐man phase 1 trial publication-title: Lancet Oncol – volume: 13 start-page: 4 issue: 1 year: 2018 article-title: Molecular profiling of lung cancer specimens and liquid biopsies using MALDI‐TOF mass spectrometry publication-title: Diagn Pathol – volume: 383 start-page: 1561 issue: 9928 year: 2014 end-page: 71 article-title: Preoperative chemotherapy for non‐small‐cell lung cancer: a systematic review and meta‐analysis of individual participant data publication-title: Lancet – volume: 21 start-page: 3016 issue: 16 year: 2003 end-page: 24 article-title: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non‐small‐cell lung cancer: the TAX 326 study group publication-title: J Clin Oncol – volume: 352 start-page: 2589 issue: 25 year: 2005 end-page: 97 article-title: Vinorelbine plus cisplatin vs. observation in resected non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 2017 year: 2017 article-title: Using deep learning for classification of lung nodules on computed tomography images publication-title: J Healthc Eng – volume: 22 start-page: e451 issue: 3 year: 2021 end-page: e65 article-title: Giant circulating cancer‐associated macrophage‐like cells are associated with disease recurrence and survival in non‐small‐cell lung cancer treated with chemoradiation and atezolizumab publication-title: Clin Lung Cancer – volume: 30 start-page: 1234 issue: 9 year: 2012 end-page: 48 article-title: Radiomics: the process and the challenges publication-title: Magn Reson Imaging – volume: 113 start-page: 37 year: 2017 end-page: 44 article-title: EGFR mutation prevalence in Asia‐Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non‐adenocarcinoma histology: The IGNITE study publication-title: Lung Cancer – volume: 16 start-page: S59 year: 2021 end-page: S61 article-title: PS01.05 surgical and clinical outcomes with neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC: LCMC3 trial primary analysis publication-title: Journal of Thoracic Oncology – volume: 11 year: 2021 article-title: Prognostic value of deep learning‐mediated treatment monitoring in lung cancer patients receiving immunotherapy publication-title: Front Oncol – volume: 37 start-page: 8503 year: 2019 article-title: Neoadjuvant atezolizumab in resectable non‐small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3) publication-title: J Clin Oncol – volume: 8 start-page: 45 issue: 1 year: 2020 end-page: 53 article-title: Efficacy, safety, and biomarker analysis of ensartinib in crizotinib‐resistant, ALK‐positive non‐small‐cell lung cancer: a multicentre, phase 2 trial publication-title: Lancet Respir Med – volume: 30 start-page: 223 issue: 4 year: 2013 end-page: 5 article-title: Al‐Jassar A. Subclassification of pulmonary non‐small cell lung carcinoma in fine needle aspirates using a limited immunohistochemistry panel publication-title: J Cytol – volume: 27 start-page: 1227 issue: 8 year: 2009 end-page: 34 article-title: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first‐line therapy for nonsquamous non‐small‐cell lung cancer: AVAil publication-title: J Clin Oncol – volume: 44 start-page: 895 issue: 8 year: 2012 end-page: 9 article-title: Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population publication-title: Nat Genet – volume: 37 start-page: 8 issue: 1 year: 2022 end-page: 15 article-title: Interpretation of updated points of 2021 CSCO guideline for non‐small‐cell lung cancer publication-title: Journal of Practical Oncology – volume: 383 start-page: 813 issue: 9 year: 2020 end-page: 24 article-title: Efficacy of Selpercatinib in RET Fusion‐Positive Non‐Small‐Cell Lung Cancer publication-title: N Engl J Med – volume: 13 start-page: 2447 year: 2021 end-page: 54 article-title: The Prevalence and Concurrent Pathogenic Mutations of KRAS (G12C) in Northeast Chinese Non‐small‐cell Lung Cancer Patients publication-title: Cancer Manag Res – volume: 12 start-page: 175 issue: 2 year: 2011 end-page: 80 article-title: New driver mutations in non‐small‐cell lung cancer publication-title: Lancet Oncol – volume: 24 start-page: 638 issue: 5 year: 2018 end-page: 46 article-title: Mechanisms and clinical activity of an EGFR and HER2 exon 20‐selective kinase inhibitor in non‐small cell lung cancer publication-title: Nat Med – volume: 7 start-page: 1617 issue: 11 year: 2021 end-page: 25 article-title: Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer: A Randomized Clinical Trial publication-title: JAMA Oncol – volume: 27 start-page: 4247 issue: 26 year: 2009 end-page: 53 article-title: Clinical features and outcome of patients with non‐small‐cell lung cancer who harbor EML4‐ALK publication-title: J Clin Oncol – volume: 37 start-page: 97 issue: 2 year: 2019 end-page: 104 article-title: SELECT: A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor‐mutant non‐small‐cell lung cancer publication-title: J Clin Oncol – volume: 16 start-page: 1909 issue: 11 year: 2021 end-page: 24 article-title: IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first‐line metastatic nonsquamous NSCLC publication-title: J Thorac Oncol – volume: 71 start-page: 209 issue: 3 year: 2021 end-page: 49 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin – volume: 109 start-page: 389 issue: 2 year: 2020 end-page: 95 article-title: Ten‐year trends of clinicopathologic features and surgical treatment of lung cancer in china publication-title: Ann Thorac Surg – volume: 20 start-page: 4285 issue: 21 year: 2002 end-page: 91 article-title: Phase III randomized trial comparing three platinum‐based doublets in advanced non‐small‐cell lung cancer publication-title: J Clin Oncol – volume: 17 start-page: 544 issue: 4 year: 2021 end-page: 57 article-title: Camrelizumab plus carboplatin and paclitaxel as first‐line treatment for advanced squamous NSCLC (CameL‐Sq): A phase 3 trial publication-title: J Thorac Oncol – volume: 1 start-page: 2 issue: 1 year: 2021 end-page: 11 article-title: Cancer incidence and mortality in China, 2015 publication-title: Journal of the National Cancer Center – volume: 28 start-page: 1843 issue: 11 year: 2010 end-page: 9 article-title: Surgery with or without preoperative paclitaxel and carboplatin in early‐stage non‐small‐cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial publication-title: J Clin Oncol – volume: 117 start-page: 20 year: 2018 end-page: 6 article-title: Community‐based lung cancer screening with low‐dose CT in China: Results of the baseline screening publication-title: Lung Cancer – volume: 72 start-page: 7 issue: 1 year: 2022 end-page: 33 article-title: Cancer statistics, 2022 publication-title: CA Cancer J Clin – volume: 106 issue: 11 year: 2014 article-title: Projected outcomes using different nodule sizes to define a positive CT lung cancer screening examination publication-title: J Natl Cancer Inst – volume: 28 start-page: 2181 issue: 13 year: 2010 end-page: 90 article-title: Meta‐analysis of concomitant versus sequential radiochemotherapy in locally advanced non‐small‐cell lung cancer publication-title: J Clin Oncol – volume: 16 start-page: 643 issue: 4 year: 2021 end-page: 52 article-title: Phase 1b study of sintilimab plus anlotinib as first‐line therapy in patients with advanced NSCLC publication-title: J Thorac Oncol – volume: 513 start-page: S2 issue: 7517 year: 2014 end-page: 3 article-title: Epidemiology: The dominant malignancy publication-title: Nature – volume: 9 start-page: 2008 issue: 5 year: 2020 end-page: 15 article-title: GEMSTONE‐301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non‐small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy publication-title: Transl Lung Cancer Res – volume: 20 start-page: 528 issue: 8 year: 2017 end-page: 37 article-title: [Risk Factors of Lung Cancer in Xuanwei, Yunnan Province, China] publication-title: Zhongguo Fei Ai Za Zhi – volume: 36 start-page: 2532 issue: 24 year: 2018 end-page: 7 article-title: Ado‐Trastuzumab Emtansine for Patients With HER2‐Mutant Lung Cancers: Results From a Phase II Basket Trial publication-title: J Clin Oncol – volume: 8 start-page: 171 issue: 5 year: 2020 article-title: Multiclassifier fusion based on radiomics features for the prediction of benign and malignant primary pulmonary solid nodules publication-title: Ann Transl Med – volume: 11 start-page: 4539 issue: 1 year: 2021 article-title: Asthma and asthma symptom control in relation to incidence of lung cancer in the HUNT study publication-title: Sci Rep – volume: 22 start-page: 247 year: 2015 end-page: 51 article-title: Detection rates and cost of lung cancer screening with low‐dose helical computed tomography among physical examination people publication-title: Chinese Journal of Cancer Prevention and Treatment – volume: 4 start-page: 652 issue: 5 year: 2009 end-page: 7 article-title: Lymph node dissection for lung cancer: significance, strategy, and technique publication-title: J Thorac Oncol – volume: 50 start-page: 882 issue: 8 year: 2021 end-page: 90 – volume: 78 start-page: 893 issue: 9 year: 2018 end-page: 911 article-title: Targeting EGFR in lung cancer: Current standards and developments publication-title: Drugs – volume: 19 start-page: 3210 issue: 13 year: 2001 end-page: 8 article-title: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small‐cell lung cancer: a Southwest Oncology Group trial publication-title: J Clin Oncol – volume: 503 start-page: 548 issue: 7477 year: 2013 end-page: 51 article-title: K‐Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions publication-title: Nature – volume: 2 issue: 4 year: 2021 article-title: Trends in molecular testing of lung cancer in mainland People's Republic of China over the decade 2010 to 2019 publication-title: JTO Clin Res Rep – volume: 7 start-page: 881 issue: 10 year: 2019 end-page: 91 article-title: Identification of risk loci and a polygenic risk score for lung cancer: a large‐scale prospective cohort study in Chinese populations publication-title: Lancet Respir Med – volume: 13 issue: 9 year: 2016 article-title: Association between adult height and risk of colorectal, lung, and prostate cancer: Results from meta‐analyses of prospective studies and mendelian randomization analyses publication-title: PLoS Med – volume: 39 start-page: 3391 issue: 30 year: 2021 end-page: 402 article-title: Amivantamab in EGFR Exon 20 Insertion‐Mutated Non‐Small‐Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study publication-title: J Clin Oncol – volume: 86 start-page: 673 issue: 9 year: 1994 end-page: 80 article-title: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non‐small‐cell lung cancer publication-title: J Natl Cancer Inst – volume: 8 start-page: 2858 issue: 6 year: 2019 end-page: 66 article-title: Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF publication-title: Cancer Med – volume: 389 start-page: 917 issue: 10072 year: 2017 end-page: 29 article-title: First‐line ceritinib versus platinum‐based chemotherapy in advanced ALK‐rearranged non‐small‐cell lung cancer (ASCEND‐4): a randomised, open‐label, phase 3 study publication-title: Lancet – volume: 383 start-page: 1328 issue: 14 year: 2020 end-page: 39 article-title: Atezolizumab for First‐Line Treatment of PD‐L1‐Selected Patients with NSCLC publication-title: N Engl J Med – volume: 32 start-page: 85 issue: 1 year: 2021 end-page: 96 article-title: Comparing nanoparticle polymeric micellar paclitaxel and solvent‐based paclitaxel as first‐line treatment of advanced non‐small‐cell lung cancer: an open‐label, randomized, multicenter, phase III trial publication-title: Ann Oncol – volume: 11 start-page: 2580 issue: 9 year: 2020 end-page: 9 article-title: Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution publication-title: Thorac Cancer – volume: 95 start-page: 414 issue: 6 year: 2018 end-page: 21 article-title: Chronic obstructive pulmonary disease in lung cancer patients: Prevalence, underdiagnosis, and clinical characterization publication-title: Respiration – volume: 365 start-page: 395 issue: 5 year: 2011 end-page: 409 article-title: Reduced lung‐cancer mortality with low‐dose computed tomographic screening publication-title: N Engl J Med – volume: 15 start-page: 816 issue: 5 year: 2020 end-page: 26 article-title: Neoadjuvant PD‐1 inhibitor (Sintilimab) in NSCLC publication-title: J Thorac Oncol – volume: 9 start-page: 1154 issue: 10 year: 2021 end-page: 64 article-title: Once‐daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non‐small‐cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single‐arm, open‐label, phase 2 study publication-title: Lancet Respir Med – volume: 14 start-page: 4275 issue: 13 year: 2008 end-page: 83 article-title: EML4‐ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer publication-title: Clin Cancer Res – volume: 121 start-page: 54 year: 2018 end-page: 60 article-title: Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment‐naïve advanced non‐squamous non‐small cell lung cancer patients publication-title: Lung Cancer – volume: 38 start-page: 2753 issue: 24 year: 2020 end-page: 61 article-title: Pyrotinib in HER2‐Mutant Advanced Lung Adenocarcinoma After Platinum‐Based Chemotherapy: A Multicenter, Open‐Label, Single‐Arm, Phase II Study publication-title: J Clin Oncol – volume: 382 start-page: 41 issue: 1 year: 2020 end-page: 50 article-title: Overall survival with osimertinib in untreated, EGFR‐mutated advanced NSCLC publication-title: N Engl J Med – volume: 35 start-page: 2613 issue: 23 year: 2017 end-page: 8 article-title: Open‐Label, Multicenter, Phase II Study of Ceritinib in Patients With Non‐Small‐Cell Lung Cancer Harboring ROS1 Rearrangement publication-title: J Clin Oncol – volume: 22 start-page: 28 issue: 1 year: 2012 end-page: 36 article-title: Effect of the interaction between outdoor air pollution and extreme temperature on daily mortality in Shanghai publication-title: China. J Epidemiol. – volume: 26 start-page: 3543 issue: 21 year: 2008 end-page: 51 article-title: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy‐naive patients with advanced‐stage non‐small‐cell lung cancer publication-title: J Clin Oncol – volume: 32 start-page: 14 issue: 1 year: 2014 end-page: 21 article-title: Kurtosis and skewness assessments of solid lung nodule density histograms: differentiating malignant from benign nodules on CT publication-title: Jpn J Radiol – volume: 28 start-page: 23 issue: 01 year: 2019 end-page: 5 article-title: Progress of cancer screening program in Urban China publication-title: China Cancer – volume: 16 start-page: 1647 issue: 10 year: 2021 end-page: 62 article-title: Liquid biopsy for advanced NSCLC: A consensus statement from the international association for the study of lung cancer publication-title: J Thorac Oncol – volume: 33 start-page: 1144 issue: 5 year: 2020 end-page: 54 article-title: The invasiveness classification of ground‐glass nodules using 3D attention network and HRCT publication-title: J Digit Imaging – volume: 41 start-page: 2758 issue: 11 year: 2017 end-page: 68 article-title: The advent of ultra‐high volume thoracic surgical centers in Shanghai publication-title: World J Surg – volume: 28 start-page: 935 issue: 5 year: 2019 end-page: 42 article-title: Elevated platelet count appears to be causally associated with increased risk of lung cancer: A mendelian randomization analysis publication-title: Cancer Epidemiol Biomarkers Prev – volume: 38 start-page: 115 issue: 2 year: 2020 end-page: 23 article-title: Gefitinib alone versus gefitinib plus chemotherapy for non‐small‐cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study publication-title: J Clin Oncol – volume: 37 start-page: 537 issue: 7 year: 2019 end-page: 46 article-title: Updated Analysis of KEYNOTE‐024: Pembrolizumab Versus Platinum‐Based Chemotherapy for Advanced Non‐Small‐Cell Lung Cancer With PD‐L1 Tumor Proportion Score of 50% or Greater publication-title: J Clin Oncol – volume: 383 start-page: 1711 issue: 18 year: 2020 end-page: 23 article-title: Osimertinib in resected EGFR‐mutated non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 70 start-page: 460 issue: 6 year: 2020 end-page: 79 article-title: Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations publication-title: CA Cancer J Clin – volume: 7 start-page: 913 issue: 5 year: 2012 end-page: 8 article-title: A novel mass spectrometry‐based assay for diagnosis of EML4‐ALK‐positive non‐small cell lung cancer publication-title: J Thorac Oncol – volume: 15 start-page: 1907 issue: 12 year: 2020 end-page: 18 article-title: Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS‐10296) in Pretreated Patients With EGFR‐Mutated Advanced NSCLC: A Multicenter, Open‐label, Phase 1 Trial publication-title: J Thorac Oncol – volume: 104 start-page: 10152 issue: 24 year: 2007 end-page: 7 article-title: Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors publication-title: Proc Natl Acad Sci USA. – volume: 12 start-page: 2807 issue: 10 year: 2021 end-page: 14 article-title: The relationship between the severity of pulmonary fibrosis and the lung cancer stage publication-title: J Cancer – volume: 10 start-page: 1243 issue: 9 year: 2015 end-page: 60 article-title: The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification publication-title: J Thorac Oncol – volume: 371 start-page: 2167 issue: 23 year: 2014 end-page: 77 article-title: First‐line crizotinib versus chemotherapy in ALK‐positive lung cancer publication-title: N Engl J Med – volume: 16 start-page: e57 issue: 8 year: 2021 end-page: e9 article-title: Over‐time risk of lung cancer is largely owing to continuing smoking exposition: A good reason to quit publication-title: J Thorac Oncol – volume: 24 start-page: 986 issue: 4 year: 2013 end-page: 92 article-title: Randomized phase 2 trial on refinement of early‐stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study publication-title: Ann Oncol – volume: 15 start-page: 1636 issue: 10 year: 2020 end-page: 46 article-title: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First‐Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double‐Blind, Phase 3 Study (Oncology pRogram by InnovENT anti‐PD‐1‐11) publication-title: J Thorac Oncol – volume: 321 start-page: 1391 issue: 14 year: 2019 end-page: 9 article-title: Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non‐Small Cell Lung Cancer Using a Clinicogenomic Database publication-title: JAMA – volume: 18 start-page: 326 issue: 1 year: 2018 article-title: Outcomes of Pemetrexed‐based chemotherapies in HER2‐mutant lung cancers publication-title: BMC Cancer – volume: 43 start-page: 243 issue: 3 year: 2021 end-page: 68 article-title: [China guideline for the screening and early detection of lung cancer(2021, Beijing)] publication-title: Zhonghua Zhong Liu Za Zhi – volume: 38 start-page: 9515 year: 2020 article-title: Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU‐667) in patients (pts) with advanced RET fusion+ non‐small cell lung cancer (NSCLC) publication-title: J Clin Oncol – volume: 355 start-page: 2542 issue: 24 year: 2006 end-page: 50 article-title: Paclitaxel‐carboplatin alone or with bevacizumab for non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 11 start-page: 85 issue: 1 year: 2016 end-page: 93 article-title: Three‐Year Follow‐Up of a Randomized Phase II Trial on Refinement of Early‐Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study) publication-title: J Thorac Oncol – volume: 11 year: 2021 article-title: Identification of the unique clinical and genetic features of chinese lung cancer patients With EGFR germline mutations in a large‐scale retrospective study publication-title: Front Oncol – volume: 81 start-page: 445 issue: 3 year: 2013 end-page: 50 article-title: A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non‐small cell lung cancer publication-title: Lung Cancer – volume: 119 start-page: 1486 issue: 8 year: 2013 end-page: 94 article-title: KIF5B‐RET fusions in Chinese patients with non‐small cell lung cancer publication-title: Cancer – volume: 90 start-page: 2369 issue: 10 year: 2016 end-page: 88 article-title: Single nucleotide polymorphisms in DNA repair genes and putative cancer risk publication-title: Arch Toxicol – volume: 216 year: 2022 article-title: Prediction of lung cancer risk based on age and smoking history publication-title: Comput Methods Programs Biomed – volume: 26 start-page: 996 issue: 12 year: 2016 end-page: 1003 article-title: Shanghai community‐based practice of early lung cancer screening with low‐dose spiral computed tomography publication-title: Chin Oncol – volume: 4 start-page: e386 issue: 9 year: 2020 end-page: e98 article-title: The effect of air pollution on deaths, disease burden, and life expectancy across China and its provinces, 1990‐2017: an analysis for the Global Burden of Disease Study 2017 publication-title: Lancet Planet Health – volume: 10 issue: 2 year: 2022 article-title: Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS‐mutated non‐small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial publication-title: J Immunother Cancer – volume: 377 start-page: 1919 issue: 20 year: 2017 end-page: 29 article-title: Durvalumab after chemoradiotherapy in stage III non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 9 start-page: 2696 issue: 6 year: 2020 end-page: 715 article-title: Expert consensus on neoadjuvant immunotherapy for non‐small cell lung cancer publication-title: Transl Lung Cancer Res – volume: 174 start-page: 269 issue: 2 year: 2014 end-page: 74 article-title: Overdiagnosis in low‐dose computed tomography screening for lung cancer publication-title: JAMA Intern Med – volume: 4 start-page: 1569 issue: 11 year: 2018 end-page: 75 article-title: Effect of anlotinib as a third‐line or further treatment on overall survival of patients with advanced non‐small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial publication-title: JAMA Oncol – volume: 179 year: 2019 article-title: Short‐term association between ambient air pollution and lung cancer mortality publication-title: Environ Res – volume: 8 start-page: 104 issue: 1 year: 2017 end-page: 10 article-title: Clinical significance of folate receptor‐positive circulating tumor cells detected by ligand‐targeted polymerase chain reaction in lung cancer publication-title: J Cancer – volume: 139 start-page: 366 issue: 2 year: 2010 end-page: 78 article-title: Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity‐matched analysis from the STS database publication-title: J Thorac Cardiovasc Surg – volume: 13 start-page: S272 issue: 10 year: 2018 end-page: S3 article-title: MS16.02 NELCIN B3 screening program in China publication-title: J Thorac Oncol – volume: 16 start-page: S927 issue: 10 year: 2021 end-page: S8 article-title: MA13.08 CHOICE‐01: A phase 3 study of toripalimab versus placebo in combination with first‐line chemotherapy for advanced NSCLC publication-title: J Thorac Oncol – volume: 13 start-page: 1302 issue: 9 year: 2018 end-page: 11 article-title: PD‐L1 immunohistochemistry comparability study in real‐life clinical samples: Results of blueprint phase 2 project publication-title: J Thorac Oncol – volume: 102 start-page: 1628 issue: 21 year: 2010 end-page: 36 article-title: Cancer risks after radiation exposure in middle age publication-title: J Natl Cancer Inst – volume: 27 start-page: 363 issue: 4 year: 2018 end-page: 79 article-title: A decade of GWAS results in lung cancer publication-title: Cancer Epidemiol Biomarkers Prev – volume: 38 start-page: 187 issue: 1 year: 1994 end-page: 92 article-title: Depression and the development of cancer: a meta‐analysis publication-title: Soc Sci Med – volume: 34 start-page: 3258 issue: 27 year: 2016 end-page: 66 article-title: Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First‐Line Therapy in Patients With Advanced Nonsquamous Non‐Small‐Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations publication-title: J Clin Oncol – volume: 11 start-page: 693 issue: 5 year: 2016 end-page: 700 article-title: Ceritinib: a Review in ALK‐Positive Advanced NSCLC publication-title: Target Oncol – volume: 7 start-page: 1 issue: 9 year: 2021 end-page: 9 article-title: Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non‐small cell lung cancer: The phase 2 KEYNOTE‐799 nonrandomized trial publication-title: JAMA Oncol – volume: 8 issue: 12 year: 2013 article-title: Quantification of rare circulating tumor cells in non‐small cell lung cancer by ligand‐targeted PCR publication-title: PLoS One – volume: 371 start-page: 1963 issue: 21 year: 2014 end-page: 71 article-title: Crizotinib in ROS1‐rearranged non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 23 start-page: 6829 issue: 28 year: 2005 end-page: 37 article-title: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non‐small‐cell lung cancer publication-title: J Clin Oncol – volume: 7 issue: 12 year: 2021 article-title: Treatment outcomes and safety of mobocertinib in platinum‐pretreated patients with EGFR exon 20 insertion‐positive metastatic non‐small cell lung cancer: A Phase 1/2 open‐label nonrandomized clinical trial publication-title: JAMA Oncol – volume: 16 start-page: S889 year: 2021 end-page: S90 article-title: MA02.02 Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non‐Small Cell Lung Cancer publication-title: J Thorac Oncol – volume: 5 start-page: 447 issue: 5 year: 2014 end-page: 54 article-title: Histological subtypes of lung cancer in Chinese women from 2000 to 2012 publication-title: Thorac Cancer – volume: 9 start-page: 456 issue: 4 year: 2014 end-page: 63 article-title: Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations publication-title: J Thorac Oncol – volume: 32 year: 2021 article-title: LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB‐IIIA NSCLC publication-title: Ann Oncol – volume: 19 start-page: 1164 issue: 3 year: 2022 article-title: Indoor air pollution increases the risk of lung cancer publication-title: Int J Environ Res Public Health – volume: 18 issue: 19 year: 2021 article-title: Excess body weight and long‐term incidence of lung and colon cancer in men; follow‐up study of 43 years publication-title: Int J Environ Res Public Health – volume: 44 start-page: 1034 issue: 20 year: 2017 end-page: 9 article-title: Low‐dose computed tomography screening for lung cancer in Tianjin: a preliminary clinical analysis of baseline screening and follow‐up results publication-title: Chinese Journal of Clinical Oncology – volume: 33 start-page: 2660 issue: 24 year: 2015 end-page: 6 article-title: Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non‐Small‐Cell Lung Cancer: KCSG‐LU05‐04 publication-title: J Clin Oncol – volume: 26 start-page: 5043 issue: 31 year: 2008 end-page: 51 article-title: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non‐small‐cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups publication-title: J Clin Oncol – year: 2022 article-title: Asbestos‐related lung cancer: Clinical characteristics and survival outcomes in an Australian cohort seeking workers compensation publication-title: Asia Pac J Clin Oncol – volume: 43 start-page: 792 issue: 8 year: 2011 end-page: 6 article-title: A genome‐wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese publication-title: Nat Genet – volume: 9 start-page: 188 year: 2010 article-title: Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression publication-title: Mol Cancer – volume: 9 start-page: 109 issue: 1 year: 2014 end-page: 13 article-title: Preselection based on clinical characteristics in German non‐small‐cell lung cancer patients screened for EML4‐ALK translocation publication-title: J Thorac Oncol – volume: 142 start-page: 2209 issue: 10 year: 2016 end-page: 16 article-title: MassARRAY, pyrosequencing, and PNA clamping for EGFR mutation detection in lung cancer tissue and cytological samples: a multicenter study publication-title: J Cancer Res Clin Oncol – volume: 14 start-page: 876 issue: 5 year: 2019 end-page: 89 article-title: Characteristics and outcomes of patients with metastatic KRAS‐mutant lung adenocarcinomas: The lung cancer mutation consortium experience publication-title: J Thorac Oncol – volume: 163 start-page: 96 year: 2022 end-page: 106 article-title: Antibody‐drug conjugates: A promising novel therapeutic approach in lung cancer publication-title: Lung Cancer – volume: 386 start-page: 241 issue: 3 year: 2022 end-page: 51 article-title: Trastuzumab deruxtecan in HER2‐mutant non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 29 start-page: 2214 issue: 11 year: 2018 end-page: 22 article-title: Alectinib versus crizotinib in treatment‐naive anaplastic lymphoma kinase‐positive (ALK+) non‐small‐cell lung cancer: CNS efficacy results from the ALEX study publication-title: Ann Oncol – volume: 77 start-page: 1131 issue: 10 year: 2017 end-page: 5 article-title: Brigatinib: First Global Approval publication-title: Drugs – volume: 20 start-page: 2837 issue: 10 year: 2020 article-title: Multi‐Level Cross Residual Network for Lung Nodule Classification publication-title: Sensors (Basel) – volume: 7 start-page: 719 issue: 9 year: 2006 end-page: 27 article-title: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB‐IIIA non‐small‐cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial publication-title: Lancet Oncol – volume: 36 start-page: 1166 issue: 2 year: 2016 end-page: 72 article-title: EGFR and KRAS mutational analysis in a large series of Italian non‐small cell lung cancer patients: 2,387 cases from a single center publication-title: Oncol Rep – volume: 33 start-page: 109 issue: 1 year: 2020 end-page: 17 article-title: The prevalence of programmed death ligand‐1 (PD‐L1) expression in non‐small cell lung cancer in an unselected, consecutive population publication-title: Mod Pathol – volume: 35 start-page: 1288 issue: 12 year: 2017 end-page: 96 article-title: Osimertinib in pretreated T790M‐positive advanced non‐small‐cell lung cancer: AURA study phase II extension component publication-title: J Clin Oncol – volume: 3 start-page: 1278 issue: 9 year: 2017 end-page: 81 article-title: Lung cancer screening with low‐dose computed tomography in the United States‐2010 to 2015 publication-title: JAMA Oncol – volume: 383 start-page: 2018 issue: 21 year: 2020 end-page: 29 article-title: First‐Line Lorlatinib or Crizotinib in Advanced ALK‐Positive Lung Cancer publication-title: N Engl J Med – volume: 178 start-page: 1420 issue: 10 year: 2018 end-page: 2 article-title: Estimation of overdiagnosis of lung cancer in low‐dose computed tomography screening: A secondary analysis of the Danish lung cancer screening trial publication-title: JAMA Intern Med – volume: 45 start-page: 1537 issue: 4 year: 2018 end-page: 49 article-title: Radiomics analysis of pulmonary nodules in low‐dose CT for early detection of lung cancer publication-title: Med Phys – volume: 91 start-page: 23 year: 2016 end-page: 8 article-title: Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations publication-title: Lung Cancer – volume: 130 start-page: 18 year: 2019 end-page: 24 article-title: Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation‐positive advanced non‐small‐cell lung cancer: Crossover extension and post‐hoc analysis of the ENSURE study publication-title: Lung Cancer – volume: 384 start-page: 2371 issue: 25 year: 2021 end-page: 81 article-title: Sotorasib for Lung Cancers with KRAS p.G12C Mutation publication-title: N Engl J Med – volume: 141 start-page: 1249 issue: 6 year: 2017 end-page: 56 article-title: Combination of chemotherapy and gefitinib as first‐line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial publication-title: Int J Cancer – volume: 393 start-page: 1819 issue: 10183 year: 2019 end-page: 30 article-title: Pembrolizumab versus chemotherapy for previously untreated, PD‐L1‐expressing, locally advanced or metastatic non‐small‐cell lung cancer (KEYNOTE‐042): a randomised, open‐label, controlled, phase 3 trial publication-title: Lancet – volume: 14 start-page: 732 issue: 4 year: 2019 end-page: 6 article-title: EGFR and ERBB2 germline mutations in chinese lung cancer patients and their roles in genetic susceptibility to cancer publication-title: J Thorac Oncol – volume: 9 start-page: 305 issue: 3 year: 2021 end-page: 14 article-title: Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy‐naive patients with advanced non‐squamous non‐small‐cell lung cancer (CameL): a randomised, open‐label, multicentre, phase 3 trial publication-title: Lancet Respir Med – volume: 3 start-page: 636 issue: 5 year: 2017 end-page: 51 article-title: Association between telomere length and risk of cancer and non‐neoplastic diseases: A mendelian randomization study publication-title: JAMA Oncol – volume: 49 start-page: 1126 issue: 7 year: 2017 end-page: 32 article-title: Large‐scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes publication-title: Nat Genet – volume: 10 start-page: 486 issue: 9 year: 2013 article-title: Epidemiology: Time to ESCAPE the city? Air pollution linked to lung cancer publication-title: Nat Rev Clin Oncol – volume: 311 start-page: 183 issue: 2 year: 2014 end-page: 92 article-title: Smoking prevalence and cigarette consumption in 187 countries, 1980‐2012 publication-title: JAMA – volume: 87 start-page: 183 year: 2021 end-page: 90 article-title: Genetically predicted insomnia and lung cancer risk: a Mendelian randomization study publication-title: Sleep Med – volume: 30 start-page: 2055 issue: 17 year: 2012 end-page: 62 article-title: Weekly nab‐paclitaxel in combination with carboplatin versus solvent‐based paclitaxel plus carboplatin as first‐line therapy in patients with advanced non‐small‐cell lung cancer: final results of a phase III trial publication-title: J Clin Oncol – volume: 7 start-page: 709 issue: 5 year: 2021 end-page: 17 article-title: Tislelizumab plus chemotherapy vs chemotherapy alone as first‐line treatment for advanced squamous non‐small‐cell lung cancer: A phase 3 randomized clinical trial publication-title: JAMA Oncol – volume: 13 start-page: 1539 issue: 10 year: 2018 end-page: 48 article-title: Results of PROFILE 1029, a Phase III Comparison of First‐Line Crizotinib versus Chemotherapy in East Asian Patients with ALK‐Positive Advanced Non‐Small Cell Lung Cancer publication-title: J Thorac Oncol – volume: 121 start-page: 725 issue: 9 year: 2019 end-page: 37 article-title: Resistance mechanisms to osimertinib in EGFR‐mutated non‐small cell lung cancer publication-title: Br J Cancer – volume: 71 start-page: 473 issue: 3 year: 1983 end-page: 9 article-title: Cigarette smoking among successive birth cohorts of men and women in the United States during 1900‐80 publication-title: J Natl Cancer Inst – start-page: 84 issue: 02 year: 2008 end-page: 7 article-title: An analysis of epidemic trends of lung cancer from 1991 to 2005 in Dalian city, liaoning province publication-title: Bulletin of Chinese Cancer – volume: 4 start-page: 364 issue: 17 year: 2022 end-page: 9 article-title: Risk of lung cancer and occupational exposure to polycyclic aromatic hydrocarbons among workers cohorts ‐ worldwide, 1969‐2022 publication-title: China CDC Wkly – volume: 29 start-page: 1 issue: 01 year: 2020 end-page: 6 article-title: Preliminary analysis of cancer screening program in Urban China from 2013 to 2017 publication-title: China Cancer – volume: 311 start-page: 1998 issue: 19 year: 2014 end-page: 2006 article-title: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs publication-title: JAMA – volume: 38 start-page: 124 issue: 2 year: 2020 end-page: 36 article-title: Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR‐mutated lung cancer publication-title: J Clin Oncol – volume: 27 start-page: 3 issue: 1 year: 2014 end-page: 9 article-title: Histological subtypes of lung cancer in Chinese males from 2000 to 2012 publication-title: Biomed Environ Sci – volume: 388 start-page: 1012 issue: 10048 year: 2016 end-page: 24 article-title: New and emerging targeted treatments in advanced non‐small‐cell lung cancer publication-title: Lancet – volume: 153 start-page: 1073 issue: 4 year: 2018 end-page: 5 article-title: Adoption Rate of Video‐Assisted Thoracic Surgery for Lung Cancer Varies Widely in China publication-title: Chest – volume: 40 start-page: 2530 issue: 23 year: 2022 end-page: 8 article-title: First‐in‐Human Phase I/IB Dose‐Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL‐1) publication-title: J Clin Oncol – volume: 101 start-page: 32 year: 2016 end-page: 9 article-title: BRAF mutations in non‐small cell lung cancer: has finally Janus opened the door? publication-title: Crit Rev Oncol Hematol – volume: 376 start-page: 629 issue: 7 year: 2017 end-page: 40 article-title: Osimertinib or platinum‐pemetrexed in EGFR T790M‐positive lung cancer publication-title: N Engl J Med – volume: 383 start-page: 931 issue: 10 year: 2020 end-page: 43 article-title: Tepotinib in non‐small‐cell lung cancer with MET Exon 14 skipping mutations publication-title: N Engl J Med – volume: 9 start-page: 702 issue: 5 year: 2014 end-page: 9 article-title: Cisplatin versus carboplatin‐based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data publication-title: J Thorac Oncol – volume: 133 start-page: 23 year: 2019 end-page: 31 article-title: Combination of icotinib and chemotherapy as first‐line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study publication-title: Lung Cancer – volume: 114 start-page: 78 issue: 1 year: 2022 end-page: 86 article-title: Incidence of lung cancer among never‐smoking Asian American, Native Hawaiian, and Pacific Islander Females publication-title: J Natl Cancer Inst – volume: 8 start-page: 1242 issue: 4 year: 2019 end-page: 8 article-title: Validation of the diagnostic efficiency of folate receptor‐positive circulating tumor cells in lung cancers: a prospective observational study publication-title: Transl Cancer Res – volume: 36 start-page: 6 issue: 1 year: 2021 end-page: 23 article-title: The regimen of computed tomography screening for lung cancer: Lessons learned over 25 years from the international early lung cancer action program publication-title: J Thorac Imaging – volume: 71 start-page: 1097 issue: 12 year: 2016 end-page: 109 article-title: The short‐term association between asthma hospitalisations, ambient temperature, other meteorological factors and air pollutants in Hong Kong: a time‐series study publication-title: Thorax – volume: 17 start-page: 423 issue: 3 year: 2021 end-page: 33 article-title: Postoperative chemotherapy use and outcomes from ADAURA: Osimertinib as adjuvant therapy for resected EGFR‐mutated NSCLC publication-title: J Thorac Oncol – volume: 23 start-page: 167 issue: 2 year: 2017 end-page: 72 article-title: Radiation exposure and lung disease in today's nuclear world publication-title: Curr Opin Pulm Med – volume: 15 start-page: 1567 issue: 10 year: 2020 end-page: 76 article-title: Lung cancer in People's Republic of China publication-title: J Thorac Oncol – volume: 7 start-page: 437 issue: 5 year: 2019 end-page: 46 article-title: Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase‐positive non‐small‐cell lung cancer (ALESIA): a randomised phase 3 study publication-title: Lancet Respir Med – volume: 39 start-page: 8511 issue: 15 year: 2021 article-title: Five‐year survival outcomes with durvalumab after chemoradiotherapy inunresectable stage III NSCLC: An update from the PACIFIC trial publication-title: J Clin Oncol – volume: 38 start-page: 3592 issue: 31 year: 2020 end-page: 603 article-title: Brigatinib Versus Crizotinib in Advanced ALK Inhibitor‐Naive ALK‐Positive Non‐Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA‐1L Trial publication-title: J Clin Oncol – volume: 6 start-page: S203 issue: 2 year: 2014 end-page: 10 article-title: VATS anatomic lung resections‐the European experience publication-title: J Thorac Dis – volume: 136 start-page: 632 issue: 3 year: 2015 end-page: 8 article-title: Home kitchen ventilation, cooking fuels, and lung cancer risk in a prospective cohort of never smoking women in Shanghai, China publication-title: Int J Cancer – volume: 13 start-page: 1167 year: 2018 end-page: 75 article-title: The link between chronic obstructive pulmonary disease phenotypes and histological subtypes of lung cancer: a case‐control study publication-title: Int J Chron Obstruct Pulmon Dis – volume: 36 start-page: 549 issue: 7 year: 2014 end-page: 54 article-title: [Results of low‐dose computed tomography (LDCT) screening for early lung cancer: prevalence in 4 690 asymptomatic participants] publication-title: Zhonghua Zhong Liu Za Zhi – volume: 140 start-page: 329 issue: 2 year: 2017 end-page: 36 article-title: Estimation of heritability for nine common cancers using data from genome‐wide association studies in Chinese population publication-title: Int J Cancer – volume: 9 start-page: 1461 issue: 11 year: 2018 end-page: 9 article-title: Real‐world EGFR testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study publication-title: Thorac Cancer – volume: 7 start-page: 387 issue: 5 year: 2019 end-page: 401 article-title: Atezolizumab plus bevacizumab and chemotherapy in non‐small‐cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open‐label phase 3 trial publication-title: Lancet Respir Med – volume: 16 start-page: 990 issue: 6 year: 2021 end-page: 1002 article-title: Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project publication-title: J Thorac Oncol – volume: 132 start-page: 69s issue: 3 year: 2007 end-page: 77s article-title: Screening for lung cancer: ACCP evidence‐based clinical practice guidelines publication-title: Chest – volume: 82 start-page: 129 issue: 1 year: 2018 end-page: 38 article-title: Exposure‐response analysis of alectinib in crizotinib‐resistant ALK‐positive non‐small cell lung cancer publication-title: Cancer Chemother Pharmacol – volume: 16 start-page: 328 issue: 3 year: 2015 end-page: 37 article-title: Necitumumab plus pemetrexed and cisplatin as first‐line therapy in patients with stage IV non‐squamous non‐small‐cell lung cancer (INSPIRE): an open‐label, randomised, controlled phase 3 study publication-title: Lancet Oncol – volume: 23 start-page: 220 issue: 2 year: 2022 end-page: 33 article-title: Sugemalimab versus placebo, in combination with platinum‐based chemotherapy, as first‐line treatment of metastatic non‐small‐cell lung cancer (GEMSTONE‐302): interim and final analyses of a double‐blind, randomised, phase 3 clinical trial publication-title: Lancet Oncol – volume: 17 start-page: 462 issue: 1 year: 2017 article-title: A multicenter survey of first‐line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non‐small cell lung cancer in China (CTONG 1506) publication-title: BMC Cancer – volume: 12 start-page: 529 issue: 3 year: 2017 end-page: 38 article-title: EGFR mutation subtypes influence survival outcomes following first‐line gefitinib therapy in advanced Asian NSCLC Patients publication-title: J Thorac Oncol – volume: 398 start-page: 1344 issue: 10308 year: 2021 end-page: 57 article-title: Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB‐IIIA non‐small‐cell lung cancer (IMpower010): a randomised, multicentre, open‐label, phase 3 trial publication-title: Lancet – volume: 42 start-page: 3 issue: 1 year: 2022 end-page: 16 article-title: Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study publication-title: Cancer Commun (Lond) – volume: 330 start-page: 153 issue: 3 year: 1994 end-page: 8 article-title: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 21 start-page: 3909 issue: 21 year: 2003 end-page: 17 article-title: Three‐arm randomized study of two cisplatin‐based regimens and paclitaxel plus gemcitabine in advanced non‐small‐cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group–EORTC 08975 publication-title: J Clin Oncol – volume: 16 start-page: 602 issue: 4 year: 2005 end-page: 10 article-title: Gemcitabine‐docetaxel versus cisplatin‐vinorelbine in advanced or metastatic non‐small‐cell lung cancer: a phase III study addressing the case for cisplatin publication-title: Ann Oncol – volume: 9 start-page: 2579 issue: 8 year: 2017 end-page: 86 article-title: Unique distribution of programmed death ligand 1 (PD‐L1) expression in East Asian non‐small cell lung cancer publication-title: J Thorac Dis – volume: 16 start-page: 1127 issue: 7 year: 2021 end-page: 35 article-title: Cannabis use, pulmonary function, and lung cancer susceptibility: A mendelian randomization study publication-title: J Thorac Oncol – volume: 68 start-page: 720 issue: 8 year: 2014 end-page: 7 article-title: Hulvej Rod N. Stressful social relations and mortality: a prospective cohort study publication-title: J Epidemiol Community Health – volume: 179 start-page: 69 issue: 1 year: 2009 end-page: 74 article-title: Plasma DNA quantification in lung cancer computed tomography screening: five‐year results of a prospective study publication-title: Am J Respir Crit Care Med – volume: 12 start-page: 208 issue: 2 year: 2017 end-page: 22 article-title: PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project publication-title: J Thorac Oncol – volume: 134 start-page: 174 year: 2019 end-page: 9 article-title: Real‐world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non‐small‐cell lung cancer: The global, multicenter EXPRESS study publication-title: Lung Cancer – volume: 383 start-page: 944 issue: 10 year: 2020 end-page: 57 article-title: Capmatinib in MET exon 14‐mutated or MET‐amplified non‐small‐cell lung Cancer publication-title: N Engl J Med – volume: 39 start-page: 713 issue: 7 year: 2021 end-page: 22 article-title: Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II‐IIIA (N1‐N2) EGFR‐mutant NSCLC: Final overall survival analysis of CTONG1104 phase III trial publication-title: J Clin Oncol – volume: 19 start-page: 130 issue: 2 year: 2018 end-page: 8 article-title: Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non‐Small‐Cell Lung Cancer publication-title: Clin Lung Cancer – volume: 9 start-page: 154 issue: 2 year: 2014 end-page: 62 article-title: A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non‐small‐cell lung cancer of adenocarcinoma histology (PIONEER) publication-title: J Thorac Oncol – volume: 10 start-page: S882 issue: 7 year: 2018 end-page: s97 article-title: Liquid biopsy for lung cancer early detection publication-title: J Thorac Dis – volume: 16 start-page: 165 issue: 2 year: 2021 end-page: 76 article-title: Osimertinib versus comparator EGFR TKI as first‐line treatment for EGFR‐mutated advanced NSCLC: FLAURA China, a randomized study publication-title: Target Oncol – volume: 40 start-page: 611 issue: 11 year: 2020 end-page: 9 article-title: The mortality of lung cancer attributable to smoking among adults in China and the United States during 1990‐2017 publication-title: Cancer Commun (Lond) – volume: 6 start-page: 863 issue: 11 year: 2018 end-page: 73 article-title: Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation‐positive non‐small‐cell lung cancer (EVAN): a randomised, open‐label, phase 2 trial publication-title: Lancet Respir Med – volume: 10 start-page: 1163 issue: 8 year: 2015 end-page: 71 article-title: Folate receptor‐positive circulating tumor cell detected by LT‐PCR‐based method as a diagnostic biomarker for non‐small‐cell lung cancer publication-title: J Thorac Oncol – volume: 188 start-page: 1984 issue: 11 year: 2019 end-page: 93 article-title: Exposure to welding fumes, hexavalent chromium, or nickel and risk of lung cancer publication-title: Am J Epidemiol – volume: 11 start-page: 473 issue: 8 year: 2014 end-page: 81 article-title: Acquired resistance to TKIs in solid tumours: learning from lung cancer publication-title: Nat Rev Clin Oncol – volume: 9 start-page: 1759 issue: 5 year: 2020 end-page: 69 article-title: KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples publication-title: Transl Lung Cancer Res – volume: 11 start-page: 1075 issue: 5 year: 2020 end-page: 81 article-title: Systematic analyses of genetic variants in chromatin interaction regions identified four novel lung cancer susceptibility loci publication-title: J Cancer – volume: 16 start-page: 1512 issue: 9 year: 2021 end-page: 22 article-title: Tislelizumab plus chemotherapy as first‐line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): A randomized phase 3 trial publication-title: J Thorac Oncol – volume: 64 start-page: 3288 issue: 9 year: 2004 end-page: 95 article-title: Disruption of cancer cell replication by alternating electric fields publication-title: Cancer Res – volume: 25 start-page: 313 issue: 3 year: 2007 end-page: 8 article-title: Induction chemoradiation and surgical resection for superior sulcus non‐small‐cell lung carcinomas: long‐term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) publication-title: J Clin Oncol – volume: 16 start-page: 519 issue: 4 year: 2021 end-page: 27 article-title: Lung cancer in Republic of China publication-title: J Thorac Oncol – volume: 41 start-page: 287 issue: 4 year: 2021 end-page: 302 article-title: Neoadjuvant immunotherapy for non‐small cell lung cancer: State of the art publication-title: Cancer Commun (Lond) – volume: 17 start-page: 411 issue: 3 year: 2021 end-page: 22 article-title: Efficacy of aumolertinib (HS‐10296) in patients with advanced EGFR T790M+ NSCLC: Updated post‐national medical products administration approval results from the APOLLO registrational trial publication-title: J Thorac Oncol – volume: 6 start-page: 34300 issue: 33 year: 2015 end-page: 8 article-title: Comprehensive investigation of oncogenic driver mutations in Chinese non‐small cell lung cancer patients publication-title: Oncotarget – volume: 14 start-page: 1233 issue: 7 year: 2019 end-page: 43 article-title: Updated Efficacy and Safety Data and Impact of the EML4‐ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK‐Positive Advanced Non‐Small Cell Lung Cancer in the Global Phase III ALEX Study publication-title: J Thorac Oncol – volume: 44 start-page: 407 issue: 3 year: 2013 end-page: 14 article-title: Is video‐assisted thoracic surgery lobectomy better than thoracotomy for early‐stage non‐small‐cell lung cancer? A systematic review and meta‐analysis publication-title: Eur J Cardiothorac Surg – volume: 18 start-page: 317 issue: 2 year: 2007 end-page: 23 article-title: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non‐small‐cell lung cancer: Four‐Arm Cooperative Study in Japan publication-title: Ann Oncol – volume: 103 start-page: 1452 issue: 19 year: 2011 end-page: 60 article-title: Sequential vs. concurrent chemoradiation for stage III non‐small cell lung cancer: randomized phase III trial RTOG 9410 publication-title: J Natl Cancer Inst – volume: 36 start-page: 1405 issue: 14 year: 2018 end-page: 11 article-title: Phase II Study of Crizotinib in East Asian Patients With ROS1‐Positive Advanced Non‐Small‐Cell Lung Cancer publication-title: J Clin Oncol – volume: 26 start-page: 3552 issue: 21 year: 2008 end-page: 9 article-title: Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group publication-title: J Clin Oncol – volume: 7 issue: 9 year: 2012 article-title: Association between chronic obstructive pulmonary disease and lung cancer: a case‐control study in Southern Chinese and a meta‐analysis publication-title: PLoS One – volume: 33 start-page: S73 year: 2022 article-title: 85P Adjuvant osimertinib in patients (pts) with stage IB–IIIA EGFR mutation‐positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis publication-title: Ann Oncol – volume: 378 start-page: 2288 issue: 24 year: 2018 end-page: 301 article-title: Atezolizumab for first‐line treatment of metastatic nonsquamous NSCLC publication-title: N Engl J Med – volume: 201 start-page: 57 issue: 1 year: 2020 end-page: 62 article-title: Pleural Plaques and the Risk of Lung Cancer in Asbestos‐exposed Subjects publication-title: Am J Respir Crit Care Med – volume: 12 issue: 8 year: 2017 article-title: Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell‐free DNA from patients with advanced lung adenocarcinoma publication-title: PLoS One – volume: 131 start-page: 1190 issue: 6 year: 2007 end-page: 203 article-title: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer publication-title: Cell – volume: 28 start-page: 777 issue: 4 year: 2017 end-page: 83 article-title: Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non‐small cell lung cancer: a multicenter randomized phase III trial publication-title: Ann Oncol – volume: 17 start-page: 889 issue: 3 year: 2010 end-page: 97 article-title: Clinicopathologic features of non‐small‐cell lung cancer with EML4‐ALK fusion gene publication-title: Ann Surg Oncol – volume: 81 issue: 13 year: 2021 article-title: Abstract CT003: Nivolumab + platinum‐doublet chemotherapy vs chemotherapy as neoadjuvant treatment for resectable (Ib‐IIIa) non‐small cell lung cancer in the phase III CheckMate 816 trial publication-title: Cancer Res – volume: 350 start-page: 351 issue: 4 year: 2004 end-page: 60 article-title: Cisplatin‐based adjuvant chemotherapy in patients with completely resected non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 346 start-page: 92 issue: 2 year: 2002 end-page: 8 article-title: Comparison of four chemotherapy regimens for advanced non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 19 start-page: 1893 issue: 8 year: 2010 end-page: 907 article-title: Global patterns of cancer incidence and mortality rates and trends publication-title: Cancer Epidemiol Biomarkers Prev – volume: 199 start-page: 1228 issue: 4 year: 2021 end-page: 36 article-title: Lung cancer occurrence‐correlation with serum chromium levels and genotypes publication-title: Biol Trace Elem Res – volume: 18 start-page: 1307 issue: 10 year: 2017 end-page: 16 article-title: Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)‐mutant metastatic non‐small‐cell lung cancer: an open‐label, phase 2 trial publication-title: Lancet Oncol – volume: 9 start-page: 829 issue: 8 year: 2021 end-page: 39 article-title: Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non‐small‐cell lung cancer: a phase 2b, multicentre, single‐arm, open‐label study publication-title: Lancet Respir Med – volume: 71 start-page: 283 issue: 4 year: 2021 end-page: 4 article-title: Pairing smoking cessation with lung cancer screening may save lives publication-title: CA Cancer J Clin – volume: 23 start-page: 209 issue: 2 year: 2022 end-page: 19 article-title: Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non‐small‐cell lung cancer in China (GEMSTONE‐301): interim results of a randomised, double‐blind, multicentre, phase 3 trial publication-title: Lancet Oncol – volume: 71 year: 2021 article-title: Leukotriene inhibition and the risk of lung cancer among U.S. veterans with asthma publication-title: Pulm Pharmacol Ther – volume: 15 start-page: 287 issue: 2 year: 2020 end-page: 95 article-title: A manifold learning regularization approach to enhance 3D CT image‐based lung nodule classification publication-title: Int J Comput Assist Radiol Surg – volume: 121 start-page: 489 issue: 9 year: 2013 end-page: 99 article-title: The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma publication-title: Cancer Cytopathol – volume: 134 start-page: 783 issue: 7 year: 2021 end-page: 91 article-title: Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 publication-title: Chin Med J (Engl) – volume: 18 start-page: 816 issue: 3 year: 2021 end-page: 24 article-title: Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non‐squamous non‐small cell lung cancer patients: a phase 3 randomized, double‐blind clinical trial publication-title: Cancer Biol Med – volume: 133 start-page: 1552 issue: 10 year: 2009 end-page: 9 article-title: Protocol for the examination of specimens from patients with primary non‐small cell carcinoma, small cell carcinoma, or carcinoid tumor of the lung publication-title: Arch Pathol Lab Med – volume: 378 start-page: 113 issue: 2 year: 2018 end-page: 25 article-title: Osimertinib in untreated EGFR‐mutated advanced non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 142 start-page: 833 issue: 4 year: 2016 end-page: 43 article-title: Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations publication-title: J Cancer Res Clin Oncol – volume: 28 start-page: 35 issue: 1 year: 2010 end-page: 42 article-title: Long‐term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin‐based chemotherapy in resected lung cancer publication-title: J Clin Oncol – volume: 285 start-page: 1182 issue: 21 year: 1971 end-page: 6 article-title: Tumor angiogenesis: therapeutic implications publication-title: N Engl J Med – volume: 16 start-page: 1501 issue: 9 year: 2021 end-page: 11 article-title: Sintilimab plus platinum and gemcitabine as first‐line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double‐blind, phase 3 trial (ORIENT‐12) publication-title: J Thorac Oncol – volume: 27 start-page: 81 issue: 1 year: 2016 end-page: 96 article-title: Fruits, vegetables and lung cancer risk: a systematic review and meta‐analysis publication-title: Ann Oncol – volume: 383 start-page: 640 issue: 7 year: 2020 end-page: 9 article-title: The effect of advances in lung‐cancer treatment on population mortality publication-title: N Engl J Med – volume: 21 start-page: 1413 issue: 11 year: 2020 end-page: 22 article-title: Neoadjuvant chemotherapy and nivolumab in resectable non‐small‐cell lung cancer (NADIM): an open‐label, multicentre, single‐arm, phase 2 trial publication-title: Lancet Oncol – volume: 6 start-page: 697 issue: 6 year: 2013 end-page: 702 article-title: Folate receptor‐positive circulating tumor cells as a novel diagnostic biomarker in non‐small cell lung cancer publication-title: Transl Oncol – year: 2012 article-title: Diagnosis value of low‐dose spiral CT for early lung cancer publication-title: Medical Recapitulate – volume: 6 issue: 224 year: 2014 article-title: Detection of circulating tumor DNA in early‐ and late‐stage human malignancies publication-title: Sci Transl Med – volume: 39 start-page: 9008 year: 2021 article-title: Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations publication-title: J Clin Oncol – volume: 8 start-page: 22 year: 2020 article-title: Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non‐small cell lung cancer patients publication-title: Biomark Res – volume: 26 start-page: 47 issue: 1 year: 2020 end-page: 51 article-title: Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration publication-title: Nat Med – volume: 21 start-page: 104 issue: 2 year: 2015 end-page: 10 article-title: Lifestyle and cancer risk publication-title: Cancer J – volume: 10 start-page: 599 issue: 5 year: 2012 end-page: 613 article-title: The management of patients with stage IIIA non‐small cell lung cancer with N2 mediastinal node involvement publication-title: J Natl Compr Canc Netw – volume: 28 start-page: 3138 issue: 19 year: 2010 end-page: 45 article-title: Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early‐stage non‐small‐cell lung cancer publication-title: J Clin Oncol – volume: 39 start-page: 9066 year: 2021 article-title: Taletrectinib (AB‐106; DS‐6051b) in metastatic non‐small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST publication-title: J Clin Oncol – volume: 45 start-page: 249 issue: 3 year: 2011 end-page: 54 article-title: [Incidence trends and pathological characteristics of lung cancer in urban Beijing during period of 1998 ‐ 2007] publication-title: Zhonghua Yu Fang Yi Xue Za Zhi – volume: 33 start-page: 2197 issue: 19 year: 2015 end-page: 204 article-title: BEYOND: A Randomized, Double‐Blind, Placebo‐Controlled, Multicenter, Phase III Study of First‐Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non‐Small‐Cell Lung Cancer publication-title: J Clin Oncol – volume: 16 start-page: S888 year: 2021 end-page: S9 article-title: MA02.01 Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion‐Positive Non‐Small Cell Lung Cancer: A Phase 2 Trial publication-title: J Thorac Oncol – volume: 10 start-page: 402 issue: 1 year: 2021 end-page: 14 article-title: Perioperative comparison of video‐assisted thoracic surgery and open lobectomy for pT1‐stage non‐small cell lung cancer patients in China: a multi‐center propensity score‐matched analysis publication-title: Transl Lung Cancer Res – volume: 29 start-page: 1409 issue: 6 year: 2018 end-page: 16 article-title: Alectinib versus chemotherapy in crizotinib‐pretreated anaplastic lymphoma kinase (ALK)‐positive non‐small‐cell lung cancer: results from the phase III ALUR study publication-title: Ann Oncol – volume: 84 start-page: 168 year: 2017 end-page: 72 article-title: The changing diagnostic pathway for lung cancer patients in Shanghai, China publication-title: Eur J Cancer – volume: 34 start-page: 953 issue: 9 year: 2016 end-page: 62 article-title: PROCLAIM: Randomized Phase III Trial of Pemetrexed‐Cisplatin or Etoposide‐Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non‐Small‐Cell Lung Cancer publication-title: J Clin Oncol – volume: 216 issue: 4 year: 2020 article-title: Polymorphisms and rare variants identified by next‐generation sequencing confer risk for lung cancer in han Chinese population publication-title: Pathol Res Pract – volume: 26 start-page: 418 issue: 4 year: 2014 end-page: 22 article-title: Safety and feasibility of video‐assisted thoracoscopic surgery for stage IIIA lung cancer publication-title: Chin J Cancer Res – volume: 32 start-page: 579 issue: 6 year: 2014 end-page: 86 article-title: Liquid biopsies: genotyping circulating tumor DNA publication-title: J Clin Oncol – volume: 28 start-page: 29 issue: 1 year: 2010 end-page: 34 article-title: Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non‐small‐cell lung cancer: updated survival analysis of JBR‐10 publication-title: J Clin Oncol – volume: 380 start-page: 668 issue: 9842 year: 2012 end-page: 79 article-title: Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross‐sectional household surveys publication-title: Lancet – volume: 17 start-page: 309 issue: 2 year: 2022 end-page: 23 article-title: IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain publication-title: J Thorac Oncol – volume: 9 start-page: 1021 issue: 9 year: 2021 end-page: 9 article-title: Icotinib versus chemotherapy as adjuvant treatment for stage II‐IIIA EGFR‐mutant non‐small‐cell lung cancer (EVIDENCE): a randomised, open‐label, phase 3 trial publication-title: Lancet Respir Med – volume: 145 start-page: 1499 issue: 6 year: 2019 end-page: 503 article-title: Is high vitamin B12 status a cause of lung cancer? publication-title: Int J Cancer – volume: 21 start-page: 67 issue: 2 year: 2018 end-page: 75 article-title: China National Lung Cancer screening guideline with low‐dose computed tomography (2018 version) publication-title: Zhongguo fei ai za zhi = Chinese Journal of Lung Cancer – volume: 448 start-page: 561 issue: 7153 year: 2007 end-page: 6 article-title: Identification of the transforming EML4‐ALK fusion gene in non‐small‐cell lung cancer publication-title: Nature – volume: 14 start-page: 606 issue: 4 year: 2019 end-page: 16 article-title: K‐ras mutation subtypes in NSCLC and associated Co‐occuring mutations in other oncogenic pathways publication-title: J Thorac Oncol – volume: 379 start-page: 2342 issue: 24 year: 2018 end-page: 50 article-title: Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC publication-title: N Engl J Med – volume: 41 start-page: 1234 issue: 11 year: 2021 end-page: 8 article-title: Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy publication-title: Cancer Commun (Lond) – volume: 39 start-page: 2339 issue: 21 year: 2021 end-page: 49 article-title: Five‐year outcomes with pembrolizumab versus chemotherapy for metastatic non‐small‐cell lung cancer with PD‐L1 tumor proportion score ≥ 50 publication-title: J Clin Oncol – start-page: 84 issue: 02 year: 2008 ident: e_1_2_16_16_1 article-title: An analysis of epidemic trends of lung cancer from 1991 to 2005 in Dalian city, liaoning province publication-title: Bulletin of Chinese Cancer – ident: e_1_2_16_18_1 doi: 10.1111/1759-7714.12121 – ident: e_1_2_16_175_1 doi: 10.1200/JCO.2019.37.15_suppl.8503 – ident: e_1_2_16_44_1 doi: 10.21037/tlcr-20-455 – ident: e_1_2_16_268_1 doi: 10.1056/NEJMoa2004407 – ident: e_1_2_16_85_1 doi: 10.1016/0277-9536(94)90314-X – ident: e_1_2_16_292_1 doi: 10.1016/j.jtho.2021.09.014 – ident: e_1_2_16_253_1 doi: 10.1056/NEJMoa1406766 – ident: e_1_2_16_43_1 doi: 10.2147/CMAR.S282617 – ident: e_1_2_16_94_1 doi: 10.1371/journal.pmed.1002118 – ident: e_1_2_16_259_1 doi: 10.1056/NEJMoa2005653 – ident: e_1_2_16_168_1 doi: 10.1016/S2213-2600(18)30277-7 – ident: e_1_2_16_234_1 doi: 10.1056/NEJMoa1408440 – ident: e_1_2_16_108_1 doi: 10.1056/NEJMoa1102873 – ident: e_1_2_16_262_1 doi: 10.1016/j.jtho.2021.08.112 – ident: e_1_2_16_193_1 doi: 10.1200/JCO.2009.27.6204 – ident: e_1_2_16_186_1 doi: 10.1093/annonc/mds578 – ident: e_1_2_16_277_1 doi: 10.1016/j.jtho.2021.11.018 – ident: e_1_2_16_38_1 doi: 10.1007/s00432-015-2081-4 – ident: e_1_2_16_50_1 doi: 10.1016/j.envint.2015.11.007 – ident: e_1_2_16_160_1 doi: 10.21037/tlcr-20-1132 – ident: e_1_2_16_210_1 doi: 10.1056/NEJMoa1713137 – ident: e_1_2_16_118_1 doi: 10.3390/s20102837 – volume: 71 start-page: 473 issue: 3 year: 1983 ident: e_1_2_16_8_1 article-title: Cigarette smoking among successive birth cohorts of men and women in the United States during 1900‐80 publication-title: J Natl Cancer Inst – ident: e_1_2_16_134_1 doi: 10.1186/s13000-017-0683-7 – ident: e_1_2_16_235_1 doi: 10.1016/j.jtho.2018.06.012 – ident: e_1_2_16_53_1 doi: 10.3322/caac.21632 – ident: e_1_2_16_80_1 doi: 10.1016/j.cmpb.2022.106660 – ident: e_1_2_16_84_1 doi: 10.7150/jca.51445 – ident: e_1_2_16_30_1 doi: 10.1001/jama.2014.3741 – ident: e_1_2_16_212_1 doi: 10.1016/j.jtho.2016.11.2225 – ident: e_1_2_16_82_1 doi: 10.1159/000487243 – volume: 27 start-page: 3 issue: 1 year: 2014 ident: e_1_2_16_17_1 article-title: Histological subtypes of lung cancer in Chinese males from 2000 to 2012 publication-title: Biomed Environ Sci – ident: e_1_2_16_286_1 doi: 10.20892/j.issn.2095-3941.2020.0212 – ident: e_1_2_16_180_1 doi: 10.1016/j.annonc.2021.08.2120 – ident: e_1_2_16_217_1 doi: 10.1200/JCO.21.00662 – ident: e_1_2_16_241_1 doi: 10.1016/S2213-2600(19)30053-0 – ident: e_1_2_16_61_1 doi: 10.1164/rccm.201901-0096OC – volume: 26 start-page: 418 issue: 4 year: 2014 ident: e_1_2_16_157_1 article-title: Safety and feasibility of video‐assisted thoracoscopic surgery for stage IIIA lung cancer publication-title: Chin J Cancer Res – ident: e_1_2_16_245_1 doi: 10.1007/s40265-017-0776-3 – ident: e_1_2_16_37_1 doi: 10.1097/JTO.0000000000000043 – ident: e_1_2_16_189_1 doi: 10.1056/NEJMoa043623 – ident: e_1_2_16_224_1 doi: 10.1016/j.jtho.2020.09.001 – ident: e_1_2_16_287_1 doi: 10.1001/jamaoncol.2018.3039 – ident: e_1_2_16_185_1 doi: 10.1016/S1470-2045(06)70804-X – ident: e_1_2_16_278_1 doi: 10.1016/j.jtho.2021.04.011 – ident: e_1_2_16_247_1 doi: 10.1093/annonc/mdy121 – ident: e_1_2_16_284_1 doi: 10.1056/NEJMoa061884 – ident: e_1_2_16_57_1 doi: 10.2188/jea.JE20110049 – ident: e_1_2_16_174_1 doi: 10.1200/JCO.2021.39.15_suppl.8503 – ident: e_1_2_16_246_1 doi: 10.1007/s00280-018-3597-5 – ident: e_1_2_16_310_1 doi: 10.1016/j.lungcan.2013.06.025 – ident: e_1_2_16_269_1 doi: 10.1016/S2213-2600(21)00084-9 – ident: e_1_2_16_110_1 doi: 10.1016/j.lungcan.2018.01.003 – ident: e_1_2_16_137_1 doi: 10.1097/JTO.0b013e31824c7f7a – ident: e_1_2_16_214_1 doi: 10.1016/j.jtho.2021.10.024 – ident: e_1_2_16_273_1 doi: 10.1056/NEJMoa1917346 – ident: e_1_2_16_192_1 doi: 10.1093/jnci/86.9.673 – ident: e_1_2_16_249_1 doi: 10.1056/NEJMoa2103695 – ident: e_1_2_16_6_1 doi: 10.1016/j.jtho.2020.10.155 – ident: e_1_2_16_133_1 – ident: e_1_2_16_142_1 doi: 10.21037/jtd.2017.08.61 – ident: e_1_2_16_301_1 doi: 10.1200/JCO.2011.39.5848 – ident: e_1_2_16_220_1 doi: 10.1038/nrclinonc.2014.104 – ident: e_1_2_16_298_1 doi: 10.1200/JCO.2002.02.068 – ident: e_1_2_16_60_1 doi: 10.1093/jnci/djq346 – ident: e_1_2_16_153_1 doi: 10.21037/tcr.2019.07.10 – ident: e_1_2_16_7_1 doi: 10.1016/j.jtho.2020.04.028 – ident: e_1_2_16_79_1 doi: 10.1097/PPO.0000000000000101 – ident: e_1_2_16_122_1 doi: 10.1155/2017/8314740 – ident: e_1_2_16_141_1 doi: 10.1016/j.lungcan.2019.06.012 – ident: e_1_2_16_124_1 doi: 10.5858/133.10.1552 – ident: e_1_2_16_242_1 doi: 10.1001/jamaoncol.2021.3523 – ident: e_1_2_16_308_1 doi: 10.1158/0008-5472.CAN-04-0083 – ident: e_1_2_16_39_1 doi: 10.1038/nature12796 – ident: e_1_2_16_96_1 doi: 10.1002/ijc.32033 – ident: e_1_2_16_13_1 doi: 10.1097/JTO.0000000000000630 – ident: e_1_2_16_92_1 doi: 10.1001/jamaoncol.2016.5945 – ident: e_1_2_16_282_1 doi: 10.1056/NEJM197111182852108 – ident: e_1_2_16_114_1 doi: 10.1001/jamainternmed.2013.12738 – ident: e_1_2_16_239_1 doi: 10.1056/NEJMoa2027187 – ident: e_1_2_16_165_1 doi: 10.1056/NEJMoa2027071 – ident: e_1_2_16_183_1 doi: 10.1200/JCO.2009.23.2272 – ident: e_1_2_16_285_1 doi: 10.1200/JCO.2014.59.4424 – ident: e_1_2_16_25_1 doi: 10.1097/JTO.0000000000000033 – ident: e_1_2_16_150_1 doi: 10.1371/journal.pone.0183331 – ident: e_1_2_16_162_1 doi: 10.1007/s00268-017-4086-4 – ident: e_1_2_16_204_1 doi: 10.1056/NEJMoa1709937 – ident: e_1_2_16_58_1 doi: 10.1136/thoraxjnl-2015-208054 – ident: e_1_2_16_171_1 doi: 10.1016/S2213-2600(21)00134-X – ident: e_1_2_16_2_1 doi: 10.1016/j.jncc.2020.12.001 – ident: e_1_2_16_176_1 doi: 10.1016/j.jtho.2021.01.320 – ident: e_1_2_16_202_1 doi: 10.1200/JCO.2015.64.8824 – ident: e_1_2_16_178_1 doi: 10.21037/tlcr-2020-63 – ident: e_1_2_16_280_1 doi: 10.1016/S1470-2045(21)00650-1 – ident: e_1_2_16_9_1 doi: 10.1158/1055-9965.EPI-10-0437 – volume: 36 start-page: 549 issue: 7 year: 2014 ident: e_1_2_16_105_1 article-title: [Results of low‐dose computed tomography (LDCT) screening for early lung cancer: prevalence in 4 690 asymptomatic participants] publication-title: Zhonghua Zhong Liu Za Zhi – volume: 4 start-page: 364 issue: 17 year: 2022 ident: e_1_2_16_66_1 article-title: Risk of lung cancer and occupational exposure to polycyclic aromatic hydrocarbons among workers cohorts ‐ worldwide, 1969‐2022 publication-title: China CDC Wkly – ident: e_1_2_16_272_1 doi: 10.1016/S0140-6736(18)32409-7 – ident: e_1_2_16_83_1 doi: 10.1016/j.pupt.2021.102084 – ident: e_1_2_16_126_1 doi: 10.4103/0970-9371.126640 – ident: e_1_2_16_223_1 doi: 10.1200/JCO.2016.70.3223 – ident: e_1_2_16_34_1 doi: 10.1200/JCO.2009.22.6993 – ident: e_1_2_16_56_1 doi: 10.1016/j.envres.2019.108748 – ident: e_1_2_16_195_1 doi: 10.6004/jnccn.2012.0062 – volume: 23 start-page: 209 issue: 2 year: 2022 ident: e_1_2_16_207_1 article-title: Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non‐small‐cell lung cancer in China (GEMSTONE‐301): interim results of a randomised, double‐blind, multicentre, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00630-6 – ident: e_1_2_16_248_1 doi: 10.1002/cac2.12227 – ident: e_1_2_16_27_1 doi: 10.1001/jama.2019.3241 – ident: e_1_2_16_211_1 doi: 10.1056/NEJMoa1913662 – ident: e_1_2_16_258_1 doi: 10.1016/S1470-2045(17)30679-4 – ident: e_1_2_16_251_1 doi: 10.1200/JCO.2016.71.3701 – ident: e_1_2_16_22_1 doi: 10.1111/1759-7714.13577 – ident: e_1_2_16_90_1 doi: 10.1093/annonc/mdv381 – volume: 29 start-page: 1 issue: 01 year: 2020 ident: e_1_2_16_102_1 article-title: Preliminary analysis of cancer screening program in Urban China from 2013 to 2017 publication-title: China Cancer – ident: e_1_2_16_264_1 doi: 10.1200/JCO.2018.77.9777 – ident: e_1_2_16_42_1 doi: 10.1186/s40364-020-00199-z – ident: e_1_2_16_221_1 doi: 10.1038/s41416-019-0573-8 – ident: e_1_2_16_236_1 doi: 10.1093/annonc/mdy405 – ident: e_1_2_16_164_1 doi: 10.1016/j.jtcvs.2009.08.026 – ident: e_1_2_16_11_1 doi: 10.1001/jama.2013.284692 – ident: e_1_2_16_146_1 doi: 10.21037/jtd.2018.03.81 – ident: e_1_2_16_219_1 doi: 10.1200/JCO.2021.39.15_suppl.9008 – ident: e_1_2_16_201_1 doi: 10.1093/annonc/mdx009 – ident: e_1_2_16_15_1 doi: 10.1038/513S2a – ident: e_1_2_16_156_1 doi: 10.1097/JTO.0b013e31819cce50 – ident: e_1_2_16_98_1 doi: 10.1001/jamaoncol.2016.6416 – ident: e_1_2_16_182_1 doi: 10.1056/NEJMoa031644 – ident: e_1_2_16_232_1 doi: 10.1016/S1470-2045(15)70046-X – ident: e_1_2_16_190_1 doi: 10.1200/JCO.2007.13.9030 – ident: e_1_2_16_275_1 doi: 10.1016/j.jtho.2020.07.014 – ident: e_1_2_16_109_1 doi: 10.1097/RTI.0000000000000538 – ident: e_1_2_16_289_1 doi: 10.1056/NEJMoa1716948 – ident: e_1_2_16_135_1 doi: 10.3892/or.2016.4874 – ident: e_1_2_16_261_1 doi: 10.1016/j.jtho.2021.08.111 – ident: e_1_2_16_127_1 doi: 10.1002/cncy.21286 – ident: e_1_2_16_179_1 doi: 10.1016/S0140-6736(21)02098-5 – ident: e_1_2_16_100_1 doi: 10.1016/j.jtho.2018.08.154 – ident: e_1_2_16_121_1 doi: 10.21037/atm.2020.01.135 – ident: e_1_2_16_154_1 doi: 10.1593/tlo.13535 – volume: 20 start-page: 528 issue: 8 year: 2017 ident: e_1_2_16_65_1 article-title: [Risk Factors of Lung Cancer in Xuanwei, Yunnan Province, China] publication-title: Zhongguo Fei Ai Za Zhi – ident: e_1_2_16_309_1 doi: 10.1073/pnas.0702916104 – ident: e_1_2_16_21_1 doi: 10.1186/s12885-018-4277-x – volume: 6 start-page: S203 issue: 2 year: 2014 ident: e_1_2_16_163_1 article-title: VATS anatomic lung resections‐the European experience publication-title: J Thorac Dis – ident: e_1_2_16_40_1 doi: 10.1016/j.jtho.2019.01.020 – ident: e_1_2_16_229_1 doi: 10.1200/JCO.2016.66.9218 – ident: e_1_2_16_31_1 doi: 10.1038/nature05945 – ident: e_1_2_16_46_1 doi: 10.1002/cac2.12099 – ident: e_1_2_16_167_1 doi: 10.1016/j.annonc.2022.02.095 – ident: e_1_2_16_216_1 doi: 10.1038/s41591-018-0007-9 – ident: e_1_2_16_76_1 doi: 10.3389/fonc.2021.774156 – ident: e_1_2_16_88_1 doi: 10.2147/COPD.S158818 – ident: e_1_2_16_172_1 doi: 10.1002/cac2.12153 – ident: e_1_2_16_256_1 doi: 10.1016/j.lungcan.2015.11.006 – ident: e_1_2_16_35_1 doi: 10.1245/s10434-009-0808-7 – ident: e_1_2_16_129_1 doi: 10.1016/j.ejca.2017.07.036 – ident: e_1_2_16_116_1 doi: 10.1002/mp.12820 – ident: e_1_2_16_230_1 doi: 10.1016/j.lungcan.2019.05.008 – year: 2012 ident: e_1_2_16_107_1 article-title: Diagnosis value of low‐dose spiral CT for early lung cancer publication-title: Medical Recapitulate – ident: e_1_2_16_227_1 doi: 10.1200/JCO.19.01488 – ident: e_1_2_16_73_1 doi: 10.1038/ng.875 – ident: e_1_2_16_148_1 doi: 10.1016/j.lungcan.2018.05.002 – volume: 26 start-page: 996 issue: 12 year: 2016 ident: e_1_2_16_103_1 article-title: Shanghai community‐based practice of early lung cancer screening with low‐dose spiral computed tomography publication-title: Chin Oncol – ident: e_1_2_16_155_1 doi: 10.1371/journal.pone.0080458 – ident: e_1_2_16_260_1 doi: 10.1200/JCO.2020.38.15_suppl.9515 – ident: e_1_2_16_233_1 doi: 10.1016/j.cllc.2017.10.004 – ident: e_1_2_16_70_1 doi: 10.1158/1055-9965.EPI-16-0794 – ident: e_1_2_16_166_1 doi: 10.1016/j.jtho.2021.10.014 – ident: e_1_2_16_243_1 doi: 10.1016/S2213-2600(19)30252-8 – ident: e_1_2_16_184_1 doi: 10.1200/JCO.2009.24.0333 – ident: e_1_2_16_197_1 doi: 10.1200/JCO.2006.08.2826 – ident: e_1_2_16_225_1 doi: 10.1016/S2213-2600(20)30455-0 – ident: e_1_2_16_29_1 doi: 10.1016/j.lungcan.2017.08.021 – ident: e_1_2_16_123_1 doi: 10.3389/fonc.2021.609054 – ident: e_1_2_16_296_1 doi: 10.1200/JCO.2003.12.046 – ident: e_1_2_16_26_1 doi: 10.1016/S0140-6736(16)31473-8 – ident: e_1_2_16_3_1 doi: 10.3322/caac.21708 – ident: e_1_2_16_281_1 doi: 10.1016/j.jtho.2021.08.181 – ident: e_1_2_16_10_1 doi: 10.1016/S0140-6736(12)61085-X – ident: e_1_2_16_41_1 doi: 10.1016/j.jtho.2018.12.013 – ident: e_1_2_16_120_1 doi: 10.1007/s11548-019-02097-8 – ident: e_1_2_16_159_1 doi: 10.1016/j.chest.2017.12.027 – volume: 39 start-page: 8511 issue: 15 year: 2021 ident: e_1_2_16_203_1 article-title: Five‐year survival outcomes with durvalumab after chemoradiotherapy inunresectable stage III NSCLC: An update from the PACIFIC trial publication-title: J Clin Oncol – ident: e_1_2_16_20_1 doi: 10.1002/cncr.27940 – ident: e_1_2_16_95_1 doi: 10.1158/1055-9965.EPI-18-0356 – ident: e_1_2_16_144_1 doi: 10.1126/scitranslmed.3007094 – ident: e_1_2_16_78_1 doi: 10.1016/j.prp.2020.152873 – ident: e_1_2_16_188_1 doi: 10.1200/JCO.2008.16.4855 – ident: e_1_2_16_67_1 doi: 10.1002/ijc.30447 – ident: e_1_2_16_125_1 doi: 10.1159/000338519 – ident: e_1_2_16_222_1 doi: 10.1056/NEJMoa1612674 – ident: e_1_2_16_194_1 doi: 10.1200/JCO.2009.26.1685 – ident: e_1_2_16_196_1 doi: 10.1016/S0140-6736(13)62159-5 – ident: e_1_2_16_238_1 doi: 10.1016/S0140-6736(17)30123-X – ident: e_1_2_16_91_1 doi: 10.1016/j.jtho.2021.03.025 – ident: e_1_2_16_170_1 doi: 10.1200/JCO.20.01820 – ident: e_1_2_16_181_1 doi: 10.1016/S1470-2045(20)30453-8 – ident: e_1_2_16_228_1 doi: 10.1200/JCO.19.01154 – ident: e_1_2_16_68_1 doi: 10.1007/s00204-016-1771-2 – ident: e_1_2_16_187_1 doi: 10.1016/j.jtho.2015.09.014 – ident: e_1_2_16_299_1 doi: 10.1200/JCO.2007.15.0375 – ident: e_1_2_16_274_1 doi: 10.1016/S2213-2600(20)30365-9 – ident: e_1_2_16_205_1 doi: 10.1056/NEJMoa1809697 – ident: e_1_2_16_294_1 doi: 10.1056/NEJMoa011954 – ident: e_1_2_16_307_1 doi: 10.1016/j.lungcan.2021.12.002 – ident: e_1_2_16_158_1 doi: 10.1093/ejcts/ezt015 – volume: 81 start-page: CT003 issue: 13 year: 2021 ident: e_1_2_16_173_1 article-title: Abstract CT003: Nivolumab + platinum‐doublet chemotherapy vs chemotherapy as neoadjuvant treatment for resectable (Ib‐IIIa) non‐small cell lung cancer in the phase III CheckMate 816 trial publication-title: Cancer Res – ident: e_1_2_16_215_1 doi: 10.1007/s11523-021-00794-6 – ident: e_1_2_16_198_1 doi: 10.1200/JCO.2009.26.2543 – ident: e_1_2_16_305_1 doi: 10.1002/cac2.12225 – ident: e_1_2_16_93_1 doi: 10.1016/j.sleep.2021.06.044 – ident: e_1_2_16_208_1 doi: 10.1001/jamaoncol.2021.2301 – ident: e_1_2_16_4_1 doi: 10.3322/caac.21660 – ident: e_1_2_16_266_1 doi: 10.1038/s41591-019-0716-8 – ident: e_1_2_16_5_1 doi: 10.1097/CM9.0000000000001474 – ident: e_1_2_16_52_1 doi: 10.1038/nrclinonc.2013.136 – ident: e_1_2_16_51_1 doi: 10.3390/ijerph19031164 – ident: e_1_2_16_89_1 doi: 10.1371/journal.pone.0046144 – ident: e_1_2_16_271_1 doi: 10.1200/JCO.21.00174 – volume: 22 start-page: 247 year: 2015 ident: e_1_2_16_106_1 article-title: Detection rates and cost of lung cancer screening with low‐dose helical computed tomography among physical examination people publication-title: Chinese Journal of Cancer Prevention and Treatment – ident: e_1_2_16_48_1 doi: 10.1016/j.jtho.2021.04.013 – ident: e_1_2_16_254_1 doi: 10.1200/JCO.2017.75.5587 – ident: e_1_2_16_136_1 doi: 10.1007/s00432-016-2211-7 – ident: e_1_2_16_147_1 doi: 10.1164/rccm.200807-1068OC – ident: e_1_2_16_267_1 doi: 10.1056/NEJMoa2002787 – ident: e_1_2_16_303_1 doi: 10.1093/annonc/mdi126 – ident: e_1_2_16_131_1 doi: 10.1186/s12885-017-3451-x – ident: e_1_2_16_24_1 doi: 10.1016/S1470-2045(10)70087-5 – ident: e_1_2_16_231_1 doi: 10.1016/j.lungcan.2019.01.016 – ident: e_1_2_16_226_1 doi: 10.1002/ijc.30806 – ident: e_1_2_16_145_1 doi: 10.1200/JCO.2012.45.2011 – ident: e_1_2_16_250_1 doi: 10.1200/JCO.21.02752 – ident: e_1_2_16_306_1 doi: 10.1016/j.annonc.2020.10.479 – volume: 45 start-page: 249 issue: 3 year: 2011 ident: e_1_2_16_14_1 article-title: [Incidence trends and pathological characteristics of lung cancer in urban Beijing during period of 1998 ‐ 2007] publication-title: Zhonghua Yu Fang Yi Xue Za Zhi – ident: e_1_2_16_45_1 doi: 10.1016/j.jtho.2021.02.016 – ident: e_1_2_16_283_1 doi: 10.1200/JCO.2007.14.5466 – ident: e_1_2_16_288_1 doi: 10.1016/j.jtho.2020.11.026 – ident: e_1_2_16_49_1 doi: 10.1093/jnci/djab143 – ident: e_1_2_16_139_1 doi: 10.1016/j.jtho.2016.11.2228 – volume: 28 start-page: 23 issue: 01 year: 2019 ident: e_1_2_16_101_1 article-title: Progress of cancer screening program in Urban China publication-title: China Cancer – ident: e_1_2_16_113_1 doi: 10.1001/jamainternmed.2018.3056 – ident: e_1_2_16_115_1 doi: 10.1016/j.mri.2012.06.010 – ident: e_1_2_16_36_1 doi: 10.1186/1476-4598-9-188 – ident: e_1_2_16_59_1 doi: 10.1097/MCP.0000000000000349 – ident: e_1_2_16_64_1 doi: 10.1093/aje/kwz187 – ident: e_1_2_16_23_1 doi: 10.18632/oncotarget.5549 – ident: e_1_2_16_71_1 doi: 10.7150/jca.35127 – ident: e_1_2_16_86_1 doi: 10.1136/jech-2013-203675 – volume: 21 start-page: 67 issue: 2 year: 2018 ident: e_1_2_16_112_1 article-title: China National Lung Cancer screening guideline with low‐dose computed tomography (2018 version) publication-title: Zhongguo fei ai za zhi = Chinese Journal of Lung Cancer – ident: e_1_2_16_81_1 doi: 10.1038/s41598-021-84012-3 – volume: 44 start-page: 1034 issue: 20 year: 2017 ident: e_1_2_16_104_1 article-title: Low‐dose computed tomography screening for lung cancer in Tianjin: a preliminary clinical analysis of baseline screening and follow‐up results publication-title: Chinese Journal of Clinical Oncology – ident: e_1_2_16_97_1 doi: 10.1378/chest.07-1349 – ident: e_1_2_16_199_1 doi: 10.1093/jnci/djr325 – ident: e_1_2_16_54_1 doi: 10.1016/S2542-5196(20)30161-3 – ident: e_1_2_16_63_1 doi: 10.1007/s12011-020-02240-6 – ident: e_1_2_16_200_1 doi: 10.1200/JCO.2014.60.0130 – ident: e_1_2_16_257_1 doi: 10.1016/j.critrevonc.2016.02.012 – ident: e_1_2_16_276_1 doi: 10.1016/j.jtho.2021.05.005 – volume: 43 start-page: 243 issue: 3 year: 2021 ident: e_1_2_16_99_1 article-title: [China guideline for the screening and early detection of lung cancer(2021, Beijing)] publication-title: Zhonghua Zhong Liu Za Zhi – ident: e_1_2_16_74_1 doi: 10.1016/S2213-2600(19)30144-4 – ident: e_1_2_16_279_1 doi: 10.1001/jamaoncol.2021.0366 – ident: e_1_2_16_77_1 doi: 10.1016/j.jtho.2018.12.006 – ident: e_1_2_16_62_1 doi: 10.1111/ajco.13664 – ident: e_1_2_16_75_1 doi: 10.1097/JTO.0000000000000130 – ident: e_1_2_16_291_1 doi: 10.1136/jitc-2021-003027 – ident: e_1_2_16_143_1 doi: 10.1038/s41379-019-0339-0 – volume: 9 start-page: 2008 issue: 5 year: 2020 ident: e_1_2_16_206_1 article-title: GEMSTONE‐301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non‐small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy publication-title: Transl Lung Cancer Res doi: 10.21037/tlcr-20-608 – ident: e_1_2_16_12_1 doi: 10.1056/NEJMoa1916623 – ident: e_1_2_16_209_1 doi: 10.1016/j.cllc.2020.06.016 – ident: e_1_2_16_130_1 doi: 10.1016/j.jtocrr.2021.100163 – ident: e_1_2_16_191_1 doi: 10.1056/NEJM199401203300301 – volume: 37 start-page: 8 issue: 1 year: 2022 ident: e_1_2_16_128_1 article-title: Interpretation of updated points of 2021 CSCO guideline for non‐small‐cell lung cancer publication-title: Journal of Practical Oncology – ident: e_1_2_16_213_1 doi: 10.1007/s40265-018-0916-4 – ident: e_1_2_16_117_1 doi: 10.1007/s11604-013-0264-y – ident: e_1_2_16_138_1 doi: 10.1200/JCO.2005.01.0793 – ident: e_1_2_16_152_1 doi: 10.7150/jca.16856 – ident: e_1_2_16_47_1 doi: 10.3322/caac.21675 – ident: e_1_2_16_240_1 doi: 10.1016/j.jtho.2019.03.007 – ident: e_1_2_16_149_1 doi: 10.1016/j.jtho.2021.06.017 – ident: e_1_2_16_218_1 doi: 10.1001/jamaoncol.2021.4761 – ident: e_1_2_16_151_1 doi: 10.1097/JTO.0000000000000606 – ident: e_1_2_16_169_1 doi: 10.1200/JCO.18.00131 – ident: e_1_2_16_32_1 doi: 10.1016/j.cell.2007.11.025 – ident: e_1_2_16_119_1 doi: 10.1007/s10278-020-00355-9 – ident: e_1_2_16_244_1 doi: 10.1007/s11523-016-0460-7 – ident: e_1_2_16_252_1 doi: 10.1016/S1470-2045(17)30680-0 – ident: e_1_2_16_295_1 doi: 10.1200/JCO.2001.19.13.3210 – ident: e_1_2_16_177_1 doi: 10.1016/j.jtho.2020.01.017 – ident: e_1_2_16_290_1 doi: 10.1016/S2213-2600(19)30084-0 – ident: e_1_2_16_302_1 doi: 10.1097/JTO.0000000000000146 – ident: e_1_2_16_55_1 doi: 10.1002/ijc.29020 – ident: e_1_2_16_72_1 doi: 10.1038/ng.2351 – ident: e_1_2_16_19_1 doi: 10.1002/cam4.2183 – ident: e_1_2_16_237_1 doi: 10.1200/JCO.20.00505 – ident: e_1_2_16_293_1 doi: 10.1016/j.jtho.2021.07.009 – volume: 4 start-page: 156 issue: 2 year: 2015 ident: e_1_2_16_28_1 article-title: Beyond ALK‐RET, ROS1 and other oncogene fusions in lung cancer publication-title: Transl Lung Cancer Res – ident: e_1_2_16_132_1 doi: 10.1111/1759-7714.12859 – ident: e_1_2_16_87_1 doi: 10.3390/ijerph181910418 – ident: e_1_2_16_140_1 doi: 10.1016/j.jtho.2018.05.013 – ident: e_1_2_16_69_1 doi: 10.1038/ng.3892 – ident: e_1_2_16_265_1 doi: 10.1056/NEJMoa2112431 – ident: e_1_2_16_111_1 doi: 10.1093/jnci/dju284 – ident: e_1_2_16_300_1 doi: 10.1093/annonc/mdl377 – ident: e_1_2_16_270_1 doi: 10.1200/JCO.18.00149 – ident: e_1_2_16_263_1 doi: 10.1200/JCO.20.00297 – ident: e_1_2_16_297_1 doi: 10.1200/JCO.2003.03.195 – ident: e_1_2_16_255_1 doi: 10.1200/JCO.2021.39.15_suppl.9066 – ident: e_1_2_16_304_1 – ident: e_1_2_16_33_1 doi: 10.1158/1078-0432.CCR-08-0168 – ident: e_1_2_16_161_1 doi: 10.1016/j.athoracsur.2019.08.017 |
| SSID | ssj0001989453 |
| Score | 2.642953 |
| SecondaryResourceType | review_article |
| Snippet | In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation... Abstract In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history,... |
| SourceID | doaj pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 937 |
| SubjectTerms | Age B7-H1 Antigen - metabolism Carcinoma, Non-Small-Cell Lung - epidemiology Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - therapy Cell death Chemotherapy Chronic obstructive pulmonary disease clinical guidelines Clinical practice guidelines clinical trials Epidermal growth factor epidermal growth factor receptor (EGFR) mutation Health risks Humans Immune Checkpoint Inhibitors Immunotherapy Kinases Lung cancer Lung Neoplasms - epidemiology Lung Neoplasms - genetics Lung Neoplasms - therapy Lymphoma Males Medical screening Mortality Mutation non‐small cell lung cancer Pathology Programmed Cell Death 1 Receptor - metabolism programmed cell death protein 1 (PD‐1) programmed death‐ligand 1 (PD‐L1) Radiation therapy Review Reviews Sarcoma Science education screening targeted therapy Tomography |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQVSkEWpQKOIAU6kz8yrGsWK166IlKvVl-RVTaZqs-7vwEfmN_SWecNNoVVbn0FiVzsL_xZL6xPJ8Z--xr16UWUgUmykpEYSqHiaSqk-7qunNRp6z2eaIWp-L4TJ6tXfVFZ8IGeeABuENMIL6WxjWSOxG49p43QXsMC5_wX5qrdcx5a8VU3l0hXXHZTHqkcBhcgO_UGNpuZKAs1P8Yu_z3kOQ6ec3ZZ_6avRppY3k0DHebvUj9Dvtysurv_vy9vnDLZUk78OUSQ7cM5Mir8rwv8-XYb9jp_Oev2aIarz2oghK6rSBy7gEnFT1EhQVFFJKnxHUHodMNxBY67xpFTafJYFXZUCLXIilIKrWx2WVb_apP71gZI_exjt5BEAgHd04ZogzIkTokgqlgXx-gsGHUBKerKZZ2UDMGS7DZDFvBPk22l4MSxqNWPwjRyYLUq_ML9KkdfWr_59OC7T34w44hdW1BUycLFtRQsIPpMwYD4ev6tLolG0q30nBRsLeD-6aRNArZkdGmYHrDsRtD3fzSn__OgtutlEYZnNu3vASemL6dHc0gP71_DiA-sJdA7Rb58OAe27q5uk37SIJu_Me83u8Bja4AyQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NbtQwEB6V9sIFUdFCaEFBhUORQp2JYztSL-2Kquqh4kCl3iz_BSot2Wq3vfMIPCNPgsfJZlm1QuIWxWPJnvF4vrE8nwHe29K0ocFQoPJ1wT1XhYmBpCiDbMuyNV6GxPZ5Kc6v-MV1fb0Bx8tamJ4fYjxwI89I-zU5uLGLoxVpqDMOP1GlZ_MEtqi2lpjzkX9ZnbAQt3iiocSYbRVVxOYjPykerbqvRaRE3P8Y2nx4afJvMJui0dlzeDbAyPykt_s2bITuBXy4nHW_f_5a_DDTaU4n8vk0unLuyLDz_KbL02PZO3B19vnr5LwYnkEonOCyKdAzZhFZ4y16ERMMz2sWApMtulZW6BtsrakEFaEGFbPMigK75EFgEKHx1S5sdrMuvILce2Z96a1Bx6NqmDFCEYSImKmNwDBkcLhUhXYDRzg9VTHVPbsxalKbTmrL4GCUve2ZMR6VOiWNjhLEZp1-zObf9OAcOoIEW9bKVDUz3DFpLauctHHrsyHGS5bB_tIeenCxhUZJlS0xwcYM3o3N0TlIv6YLs3uSofBbK8YzeNmbbxxJJSJaUlJlINcMuzbU9Zbu5nsi4G7qWgkV5_YxLYF_TF9PTiaYvl7_j_AePEUqs0iXBvdh825-H95E8HNn36Y1_gf7mftF priority: 102 providerName: Wiley-Blackwell |
| Title | Non‐small cell lung cancer in China |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcac2.12359 https://www.ncbi.nlm.nih.gov/pubmed/36075878 https://www.proquest.com/docview/2724243832 https://www.proquest.com/docview/2712845804 https://pubmed.ncbi.nlm.nih.gov/PMC9558689 https://doaj.org/article/266b158a350a4c07bb03c7b763be4290 |
| Volume | 42 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwEB7R9sIFFfEXKKsg4ABSqDNxYueE2mWrisNSIYr2ZvkvpdKStLvtnUfgGXkSPN5syoqqtySegz3j8Xye2N8AvDG5bnyNPkPpyow7LjMdAkmWe9HkeaOd8JHtc1odn_LPs3LWJ9yW_bHK9ZoYF2rXWcqR76OgiwxhP4UfLy4zqhpFf1f7EhpbsEPUZXSkS8zETY6F2MXLYmAlxX2rLX6g66H1RhyKdP23Ycz_j0r-C2FjDDrahQc9eEwPVtZ-CPd8-wjeTrv2z6_fy596Pk8pD5_OgwOnlsy5SM_bNJbIfgynR5Nv4-OsL36Q2YqLOkPHmEFktTPoqrCtcLxk3jPRoG1Ega7GxuiioqunXoa9ZUHhXHBfoa987YonsN12rX8GqXPMuNwZjZYHdTCtK0nAISClJsBBn8C7tSqU7ZnBqUDFXK04jVGR2lRUWwKvB9mLFR_GrVKHpNFBgjis44ducaZ6l1ABGpi8lLoomeaWCWNYYYUJC57xIUqyBPbW9lC9Yy3VzTRI4NXQHFyC9Ktb312TDAXdUjKewNOV-YaeFFXASFLIBMSGYTe6utnSnv-ItNt1WcpKhrG9j1PgjuGr8cEY49Pzu8fwAu4jXaeIhwP3YPtqce1fBpBzZUawhfxkFOfzCHYOJ9OTr6OYMAhvX75PJp_-Ag-E_f0 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB6V7QEuFYi_QIEg6AGkUGfixMkBoXZptaVlhVAr9Zb6L7TSkpTdVogbj8CT8FA8CWNvkrKi6q23KB5F9vx4vnE8MwAvVSwrW6CNMDdpxA3PI0mOJIqtqOK4kkZYX-1znI0O-IfD9HAJfne5MO5aZbcn-o3aNNqdka-jcIkMFE_hu9Nvkesa5f6udi005mqxa398p5Bt9nbnPcl3DXF7a384itquApHOuCgiNIwpRFYYhSYjvG54yqxlokJdiQRNgZWSSeZyOm1OQVvi_KTgNkOb2cIk9N0bsMwTCmUGsLy5Nf70-eJUx9UzT5O-Diqua6nxjUtILRY8n28QcBmq_f9y5r-g2Xu97duw0sLVcGOuX3dgydZ3YW3c1H9-_pp9lZNJ6E7-wwltGaF2CjQNT-rQN-W-BwfXwpj7MKib2j6E0BimTGyURM2JHUzKLHdQhbBZRQDUBvCqY0Wp21rkriXGpJxXUcbSsa30bAvgRU97Oq_AcSnVpuNoT-GqZvsXzfRL2RphSWBExWkuk5RJrplQiiVaKNpilSW_zAJY7eRRtqY8Ky8UL4Dn_TAZoeOvrG1z7micm09zxgN4MBdfPxPSE4rJRB6AWBDswlQXR-qTY1_ou0jTPMtpba-9Clyx_HK4MUT_9OjqNTyDm6P9j3vl3s549zHcQpfM4a8mrsLgbHpunxDEOlNPW70O4ei6TekvIlk1Hw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NbtQwEB6VVkJcEBV_gVKCgANIoc7EsR2pl-3CqvxoxYFFFRfLjh2otGSrbXvnEXhGngSPk82yokLiFsUjy57xeL6xPJ8BntncNL5Cn6FyZcYdV5kJgSTLvWzyvDFO-sj2ORXHM_7upDzZgsNVLUzHDzEcuJFnxP2aHPzMNQdr0tDa1PiKKj2ra7BDNHlhTe-MPs--zNZnLMQuHokoMeRbWRHQ-cBQigfrDjZiUqTuvwpv_n1t8k84G-PR5Bbc7IFkOuosvwtbvr0Nz6eL9tePn-ffzXye0pl8Og_OnNZk2mV62qbxuew7MJu8-TQ-zvqHELJacFll6BiziKxyFp0IKYbjJfOeyQbrRhboKmysKQSVoXoV8syCQrvkXqAXvnLFXdhuF62_D6lzzLrcWYM1D6phxghFICKgpiZAQ5_Ai5UqdN2zhNNjFXPd8RujJrXpqLYEng6yZx03xpVSR6TRQYL4rOOPxfKr7t1DB5hg81KZomSG10xay4pa2rD5WR8iJktgb2UP3TvZuUZJtS0hxcYEngzNwT1Iv6b1i0uSoQBcKsYTuNeZbxhJIQJeUlIlIDcMuzHUzZb29Fuk4K7KUgkV5vYyLoF_TF-PR2OMXw_-R_gxXP_4eqI_vJ2-fwg3kGou4g3CPdi-WF76RwEJXdj9fsH_Bucd_6k |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Non%E2%80%90small+cell+lung+cancer+in+China&rft.jtitle=Cancer+communications+%28London%2C+England%29&rft.au=Chen%2C+Peixin&rft.au=Liu%2C+Yunhuan&rft.au=Wen%2C+Yaokai&rft.au=Zhou%2C+Caicun&rft.date=2022-10-01&rft.issn=2523-3548&rft.eissn=2523-3548&rft.volume=42&rft.issue=10&rft.spage=937&rft.epage=970&rft_id=info:doi/10.1002%2Fcac2.12359&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_cac2_12359 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2523-3548&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2523-3548&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2523-3548&client=summon |